生意宝 | 全球化工网 | 韩国化工网 | ChinaChemNet点击下载生意通,与百万生意人谈生意! ·免费注册 ·用户登录 ·服务中心 
  • 中国化工网首页 >> 化工助手 >> FDA药品专利信息 >> 专利用途代码释义


    专利用途代码 代码含义
    U Patent Use Code (See Individual References)
    U-1 Prevention Of Pregnancy
    U-10 Diagnostic Method For Distinguishing Between Hypothalmic Malfunctions Or Lesions In Humans
    U-100 Method Of Treating Ocular Inflammation
    U-1000 Adjunctive Therapy To Diet In Patients With Hyperlipidemias
    U-1001 Method For Delivering Drug To Lung Of Mammal, Comprising Administering Drug Product By Inhalation. Treating A Mammal Having A Condition Capable Of Treatment By Inhalation, Comprising Administering To The Lung The Drug Product By Inhalation
    U-1002 Method Of Treating Inflammatory Conditions
    U-1003 A Method Of Myocardial Perfusion Imaging And Increasing Coronary Blood Flow
    U-1004 Treatment Of Patients With Relapsed Or Refractory Peripheral T-Cell Lymphoma
    U-1005 Method Of Treating A Staphylococcal Infection
    U-1006 New Combination Product For The Early Treatment Of Recurrent Herpes Labialis (Cold Sores) To Reduce The Likelihood Of Ulcerative Cold Sores And To Shorten The Lesion Healing Time In Adults And Adolescents (12 Years Of Age And Older)
    U-1007 Method Of Treating Gout Flares
    U-1008 Application Of Antiseptic With Moisturizers For Surgical And Healthcare Personnel Skin Disinfection
    U-1009 Method For Administration Of Testosterone
    U-101 Adjunct To Conventional Ct Or Mri Imaging In The Localization Of Stroke In Patients In Whom Stroke Has Already Been Diagnosed
    U-1010 To Reduce Blood Phenylalanine Levels In Patients With Hyperphenylalaninemia Due To Tetra Hydrobiopterin Responsive Phenylketonuria. Kuvan Should Be Taken Orally With Food To Increase Absorption
    U-1011 Use Of Granisetron Transdermal System To Treat/Prevent Chemotherapy Induced Nausea And Vomiting
    U-1012 Method For Treating Insomnia While Reducing The Risk Of An Adverse Drug Interaction
    U-1013 Method Of Using Ribavirin In Combination With Pegylated Interferon Alpha-2b To Treat Patients With Chronic Hepatitis C
    U-1014 Method Of Using Ribavirin In Combination With Interferon Alpha-2b(Pegylated And Nonpegylated) To Treat Patients With Chronic Hepatitis C
    U-1015 Treatment Of Patients With Relapsed Or Refractory Peripheral T-Cell Lymphoma
    U-1016 In Combination With Other Antiretroviral Agents For The Treatment Of Hiv-1 Infection In Treatment-Experienced Adult Patients, Who Have Evidence Of Viral Replication And Hiv-1 Strains Resistant To An Nnrti And Other Antiretroviral Agents
    U-1017 A Method Of Treating Nasal And Non-Nasal Symptoms Of Seasonal Allergic Rhinitis
    U-1018 Treatment Of Pulmonary Hypertension By Inhalation
    U-1019 Treatment Of Pulmonary Hypertension
    U-102 Method Of Hormonally Treating Menopausal Or Post-Menopausal Disorders In Women
    U-1020 Method Of Using Colchicine For The Prophylaxis Of Gout Flares
    U-1021 Short-Term Treatment (4-8 Weeks) Of Active Benign Gastric Ulcer
    U-1022 For The Preparation Of Skin Prior To Surgery; Helps Reduce Bacteria That Can Potentially Cause Skin Infection
    U-1023 Treatment Of Atrophic Vaginitis Due To Menopause
    U-1024 Reduction Of Elevated Intraocular Pressure In Patients With Glaucoma Or Ocular Hypertension Who Require Adjunctive Or Replacement Therapy Due To Inadequately Controlled Iop
    U-1025 Treating Frequent Heartburn
    U-1026 A Method Of Treating Human Suffering From Or Susceptible To Psychosis.
    U-1027 Reduction Of Elevated Plasma Sterol And/Or Stanol Levels In A Mammal
    U-1028 A Method Of Distributing Sodium Oxybate Under Control Of A Central Pharmacy
    U-1029 Method For Treating Acute Elevations Of Blood Pressure In Human Subject In Need Thereof
    U-103 Treatment Of Ocular Hypertension
    U-1030 Improvement Of Walking In Patients With Multiple Sclerosis (Ms)
    U-1031 Improve Respiratory Symptoms In Cystic Fibrosis In Patients With Pseudomonas Aeruginosa
    U-1032 Use Of Rosuvastatin Calcium For The Primary Prevention Of Cardiovascular Disease In Individuals Without Clinically Evident Coronary Heart Disease But With Increased Risk Factors
    U-1033 Topical Treatment Of Acne Vulgaris
    U-1034 Treatment Of Attention Deficit Hyperactivity Disorder (Adhd) In Adults
    U-1035 Nonsteroidal Anti-Inflammatory Drug Indicated For Relief Of Mild To Moderate Acute Pain
    U-1036 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Insulin
    U-1037 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-Iv Inhibitor In Combination With A Ppar-Gamma Agonist
    U-1038 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Metformin And A Ppar-Gamma Agonist
    U-1039 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Metformin
    U-104 Treatment Of Aqueous Humor Formation And Intraocular Pressure
    U-1040 Inhibition Of Thrombin In A Patient
    U-1041 Treatment Of Disorders Responsive To Growth Hormone
    U-1042 Method For Stimulating Coronary Vasodilation For Purposes Of Imaging The Heart
    U-1043 Management Of Moderate To Severe Pain
    U-1044 Topical Treatment Of Scalp Psoriasis
    U-1045 Maintenance Treatment In Patients With Locally Advanced Or Metastatic Nsclc Who Have Not Progressed On 1st-Line Treatment Wth Platinum-Based Chemotherapy
    U-1046 Maintenance Treatment Of Patients With Locally Advanced Or Metastatic Nsclc Whose Disease Has Not Progressed After Four Cycles Platinum-Based Chemotherapy
    U-1047 Treatment Of Biopsy-Confirmed, Primary Superficial Basal Cell Carcinoma (Sbcc)
    U-1048 Works Through The Induction Of Interferon And Other Cytokines
    U-1049 Prophylaxis Of Organ Rejection In Adult Patients At Low-Moderate Immunologic Risk Receiving A Renal Transplant
    U-105 Emesis
    U-1050 Use Of Metaxalone For Treatment Of Musculskeletal Conditions
    U-1051 Treatment Of Oropharyngeal Candidiasis
    U-1052 Relief Of Signs And Symptoms Of Arthritis And Risk-Reduction Of Nsaid-Associated Gastric Ulcer
    U-1053 Risk-Reduction Of Nsaid-Associated Gastric Ulcer
    U-1054 Onychomycosis Of The Toenail Caused By Tricophyton Rubrum Or Trichophyton Mentagrophytes, Once Daily Use For 12 Consecutive Weeks
    U-1055 An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus Who Are Already Treated With A Thiazolidinedione (Tzd) And Metformin Or Who Have Inadequate Glycemic Control On A Tzd Or Metformin Alone
    U-1056 Treatment Of Pain Using A Nasal Spray Of Ketorolac Tromethamine
    U-1057 Treatment Of Inflammation And Pain Using A Nasal Spray Of Ketorolac Tromethamine
    U-1058 Use Of Thalidomide In Combination With Dexamethasone For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma
    U-1059 Adjunctive Therapy To Diet To Patients With Hypertriglyceridemia
    U-106 Treatment Of Epilepsy
    U-1060 Adjunctive Therapy To Diet In Patients With Elevated Cholesterol And/Or Lipid Levels
    U-1061 Adjunctive Therapy To Diet In Patients With Mixed Dyslipidemia
    U-1062 Administration Of Approved Product For Treatment Of Alzheimer's Disease
    U-1063 Treatment Of Only Inflammatory Lesions (Papules And Pustules) Of Rosacea
    U-1064 Treatment Of Bipolar Disorder And Schizophrenia
    U-1065 Method Of Treating Androgen Responsive Or Medicated Condition In A Mammal By Administering A Safe & Effective Amount Of Dutasteride Or A Pharmaceutically Acceptable Solvate Thereof.. Conditions Include Benign Prostatic Hypertrophy
    U-1066 Method Of Treating An Androgen Response Or Mediated Disease In A Mammal By Admininstering An Effective Androgen Responsive Or Medicated Disease Amount Of Dutasteride..Conditions Include Benign Prostatic Hyperplasia
    U-1067 Treatment Of Cancer
    U-1068 Treatment Of Asthma
    U-1069 A Method Of Treating A Patient With A Prescription Drug Using An Exclusive Computer Database In A Computer System For Distribution
    U-107 Treatment Of Hypertension And Angina Pectoris
    U-1070 A Method To Control Abuse Of A Sensitive Drug By Controlling With A Computer Processor The Distribution Of The Sensitive Drug Via An Exclusivity Central Pharmacy That Maintains A Central Database
    U-1071 Method Of Treating Bladder Dsyfunction With Once A Day Trospium Salt Formulation
    U-1072 The Management Of Moderate To Severe Chronic Pain In Patients Requiring A Continuous, Around-The-Clock Opioid Analgesic For An Extended Period Of Time
    U-1073 Use For The Treatment Of Asthma And Copd
    U-1074 Use Of Exenatide May Result In Reduction In Body Weight
    U-1075 Use For The Treatment Of Asthma
    U-1076 Reduce Chronic Severe Drooling (I.E., Sialorrhea) In Patients With Neurologic Conditions Associated With Problem Drooling
    U-1077 Pretreatment Of Patients With Vitamin B12 And Folic Acid Prior To Pemetrexed Disodium Administraion
    U-1078 Treatment Of Acne
    U-1079 Revlimid (Lenalidomide) Is Indicated For The Treatment Of Patients With Transfusion-Dependent Anemia In Myelodysplastic Syndromes (Mds)
    U-108 Short-Term Treatment Of Active Duodenal Ulcer, Gastroesophageal Reflux Disease (Gerd), Severe Erosive Esophagitis, Poorly Responsive Symptomatic Gerd And Pathologial Hypersecretory Conditions And Maintenance Healing Of Erosive Esophagitis
    U-1080 Method To Treat Pulmonary Hypertension By Administering Ambrisentan To A Patient
    U-1081 Lumigan Is A Prostaglandin Analog Indicated For The Reduction Of Elevated Intraocular Pressure In Patients With Open Angle Glaucoma Or Ocular Hypertension
    U-1082 Use Of A Combination Of Tobramycin And Dexamethasone To Treat Ocular Inflammation Where An Infection Or Risk Of Infection Exists
    U-1083 Acute Treatment Of Migraine Attacks, With Or Without Aura, And The Treatment Of Cluster Headache Episodes
    U-1084 Relief Of The Inflammatory And Pruritic Manifestations Of Corticosteroid Responsive Dermatoses In Patients 12 Years Of Age Or Older
    U-1085 Method For Treating Irritable Bowel Syndrome And Method For Treating Abdominal Discomfort Associated With Irritable Bowel Syndrome
    U-1086 Treatment Of Autoimmune Disease
    U-1087 Detection Of Non-Muscle Invasive Papillary Cancer Of The Bladder By Photodynamic Cystoscopy
    U-1088 Relief Of Muscle Spasm
    U-1089 Inhibition Of Thrombin
    U-109 Adjunct Diet In The Tx Of Elevated Total Cholesterol And Ldl-C Levels In Pts W/Primary Hypercholesterolemia Whose Response To Dietary Restriction Of Sat Fat And Cholesterol And Other Nonpharmacological Measures Has Not Been Adequate
    U-1090 Lo Loestrin Fe Is Indicated For The Prevention Of Pregnancy In Women Who Elect To Use Oral Contraceptives As A Methof Of Contraception
    U-1091 Assessment Of Bronchial Hyperresponsiveness In Patients 6 Years Of Age Or Older Who Do Not Have Clinically Apparent Asthma
    U-1092 Treatment Of Breast Cancer
    U-1093 Treatment Of Pseudobulbar Affect
    U-1094 Management Of Chronic Musculoskeletal Pain
    U-1095 Method Of Treating Ocular Inflammation
    U-1096 Treatment Of Patients With Metastatic Breast Cancer
    U-1097 Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus When Treatment With Both Saxagliptin And Metformin Is Appropriate
    U-1098 Method Of Treating Hyperparathyroidism; Method Of Treating Hypercalcemia
    U-1099 Treatment Of Pain, Including Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, And Fibromyalgia
    U-11 Treatment Or Prophylaxis Of Cardiac Disorders
    U-110 Use As A Retrievable Perssary
    U-1100 Reduction Of Excess Abdominal Fat In Hiv-Infected Patients With Lipodystrophy
    U-1101 Method Of Treating Excessive Daytime Sleepiness In Patients With Narcolepsy
    U-1102 Method Of Treating Cataplexy In Patients With Narcolepsy
    U-1103 Testosterone Replacement Therapy In Males For Conditions Associated With A Deficiency Or Absence Of Endogenous Testosterone
    U-1104 Use Of Tramadol For The Management Of Moderate To Moderately Severe Chronic Pain
    U-1105 Topical Treatment Of Head Lice Infestation In Patients Four (4) Years Of Age And Older
    U-1106 Treating Hypertriglyceridemias With Reduction Of Food Effect
    U-1107 Treating Hypercholesterolemias With Reduction Of Food Effect
    U-1108 Treating Type 2 Diabetes Mellitus With Exenatide By Stimulating Insulin Release
    U-1109 Treatment Of Cutaneous Manifestations Of Erythema Nodosum Leprosum (Enl) In Connection With A Special Program Approved By Fda Called “System For Thalidomide Education And Prescribing Safety“ (S.T.E.P.S.)
    U-111 Diabetes
    U-1110 Method Of Treating A Patient With A Prescription Drug Using A Computer Database In A Computer System For Distribution
    U-1111 Nonsteroidal Anti-Inflammatory Drug Indicated For Relief Of Mild To Moderate Acute Pain
    U-1112 Method Of Mr Imaging Of A Mammal
    U-1113 Treatment And Prophylaxis Of Influenza
    U-1114 Treatment With Gabapentin, Including Treatment Of Neuropathic Pain, Including Neuropathic Pain Associated With Postherpetic Neuralgia
    U-1115 Treatment To Reduce The Risk Of Copd Exacerbations In Patients With Severe Copd Associated With Chronic Bronchitis And A History Of Exacerbations
    U-1116 Method Of Administering Colchicine To Familial Mediterranean Fever Patients
    U-1117 Treatment Of Breast Cancer
    U-1118 Use For The Treatment Of Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And Emphysema
    U-1119 Contrast Agent For Magnetic Resonance Imaging
    U-112 Contraception
    U-1120 To Reduce Gastrointestinal Side Effects Administer With A Meal; As Starting Dose Administer Once Daily With Evening Meal
    U-1121 Method Of Treating Travelers' Diarrhea
    U-1122 Treatment Of Secondarily Infected Traumatic Skin Lesions Due To S. Aureus And S. Pyogenes
    U-1123 Treatment Of Alcohol Dependence
    U-1124 Prevention Of Relapse To Opioid Dependence, Following Opioid Detoxification
    U-1125 Method For The Detection Of Neuroendocrine Tumors
    U-1126 Use In Combination With Prednisone For The Treatment Of Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel
    U-1127 Treatment Of Patent Ductus Arteriosus
    U-1128 Treatment Of Chronic Hepatitis C (Chc) Genotype 1 Infection In Combination With Peginterferon Alfa And Ribavirin In Adult Patients (>=18 Years Of Age) With Compensated Liver Disease
    U-1129 Treatment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin
    U-113 Method Of Conducting Radiological Examination Of A Patient By Administering To Said Patient A Radiopaque Amount Of Iopromide
    U-1130 Secondary Prevention Of Cardiovascular Events By Dosing Once Per Day In The Evening Or A Night With Pretreatment With A Flush Inhibiting Agent Such As Aspirin
    U-1131 Treatment Of Hypertriglyderidemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin
    U-1132 Treatment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night
    U-1133 Secondary Prevention Of Cardiovascular Events By Dosing Once Per Day In The Evening Or At Night
    U-1134 Treatment Of Hypertriglyceridemia By Dosing Once Per Day In The Evening Or At Night
    U-1135 Treatment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A) And Increase Of Hdl-C
    U-1136 Secondary Prevention Of Cardiovascular Events By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C
    U-1137 Treatment Of Hypertriglyceridemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C
    U-1138 Treatment Of Primary And Mixed Dyslipidemia By Dosing Once Per Day In The Evening Or At Night
    U-1139 Reduction In Risk Of Recurrent Nonfatal Myocardial Infarction By Dosing Once Per Day In The Evening Or At Night
    U-114 Use For Inhibiting Bone Resorption
    U-1140 Reduction In Elevated Tc And Ldl-C By Dosing Once Per Day In The Evening Or At Night
    U-1141 Reduction In Tg By Dosing Once Per Day In The Evening Or At Night
    U-1142 Treatment Of Primary And Mixed Dyslipidemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibiting Agent Such As Aspirin
    U-1143 Reduction In Risk Of Recurrent Nonfatal Myocardial Infarction By Dosing Once Per Day In The Evening Or A T Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin
    U-1144 Reduction In Elevated Tc And Ldl-C By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin
    U-1145 Reduction In Tg By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibiting Agent Such As Aspirin
    U-1146 Reduction In Tg With Reduced Flushing By Dosing Once Per Day In The Evening Or At Night
    U-1147 Treatment Of Primary And Mixed Dyslipidemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C
    U-1148 Reduction In Risk Of Recurrent Nonfatal Myocardial Infarction By Dosing Once Per Day In The Evening Or At Night, Through Reductino Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C
    U-1149 Treatment Of Hypertriglyceridemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibiting Agent Such As Aspirin
    U-115 Use Of Vasodilators To Effect And Enhance An Erection (And Thus Treat Erectile Dysfunction), By Injection Into The Penis
    U-1150 Tretment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction In Total-C, Ldl-C, Tg, Lp(A), And Increase Of Hdl-C
    U-1151 Treatment Of Hypertriglycderidemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction In Total-C, Ldl-C, Lp(A), And Increase Of Hdl-C
    U-1152 Cyanocobalamin Administration Through Nasal Infusion
    U-1153 In Combination With Other Antiretroviral Agents, Is Indicated For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Antiretroviral Treatment-Naive Adult Patients, As Set Forth In The Labeling, Including I&U Section
    U-1154 Treatment Of Protein Kinase Related Disorders, Such As Gastrointestinal Stromal Tumors, Renal Cell Carcinoma And Advanced Pancreatic Neuroendocrine Tumors, With Sunitinib
    U-1155 Use Of Thalidomide In Treatment Of Cutaneous Manifestations Of Erythema Nodosum Leprosum (Enl)
    U-1156 To Reduce Blood Phenylalanine (Phe) Levels In Patinets With Hyperphenylalaninemia (Hpa)
    U-1157 Relief Of Symptoms Associated With Respiratory Allergies In Adults And Children 2 Years Of Age And Older And For The Relief Of Symptoms Associated With Hives (Urticaria) In Adults And Children 6 Years Of Age And Older
    U-1158 Relief Of Symptoms Associated With Respiratory Allergies And For The Relief Of Symptoms Associated With Hives (Urticaria) In Adults And Children 6 Years Of Age And Older
    U-1159 Relief Of Symptoms Associated With Respiratory Allergies, Swelling Of The Nasal Passages And Sinus Congestion And Pressure In Adults And Children 12 Years Of Age And Older
    U-116 Method Of Myocardial Imaging
    U-1160 Relief Of Symptoms Associated With Respiratory Allergies And For The Relief Of Symptoms Associated With Hives (Urticaria) In Adults And Children 6 Years Of Age And Older And 12 Years Of Age And Older
    U-1161 For The Treatment And Prophylaxis Of Gout Flares & The Treatment Of Familial Mediterranean Fever
    U-1162 Treatment Of Seborrheic Dermatitis Of The Scalp
    U-1163 Method Of Treating Thrombosis
    U-1164 Method Of Treating An Argatroban Treatable Condition
    U-1165 Use For The Treatment Of Multiple Myeloma
    U-1166 A Method For Treatment Of Gout Flares During Prophylaxis
    U-1167 Prophylaxis Of Deep Vein Thrombosis (Dvt)
    U-1168 The Long Term, Once-Daily Maintenance Brochodilator Treatment Of Airflow Obstruction In Patients With Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And/Or Emphysema
    U-1169 Management Of Breakthrough Pain In Cancer Patients 18 Years Of Age And Older Who Are Receiving And Tolerant To Opioid Therapy For Their Underlying Persistent Cancer Pain
    U-117 Treatment Of Ocular Allergic Response In Human Eyes
    U-1170 Treatment Of Hiv-1 Infection In Pediatric Patients 12 Years Of Age And Older
    U-1171 Reduction Of The Rate Of Thrombotic Events In Patients With Acute Coronary Syndrome
    U-1172 To Reduce Elevated Total-C, Apo B, And Non-Hdl-C In Patients Wiht Primary Hyperlipidemia By Administration Of Ezetimibe In Combination With A Statin
    U-1173 To Reduce Elevated Total-C, Ldl-C, Apo B And Non-Hdl-C In Patients With Primary Hyperlipidemia By Administration Of Ezetimibe Alone Or In Combination With A Statin Or With Fenofibrate
    U-1174 Administration Of Remodulin Diluted For Intravenous Infusion With Sterile Water For Injection, 0.9% Sodium Chloride Injection, Or Flolan Steriile Diluent For Injection Prior To Administration
    U-1175 Reduction Of Cardiac Tissue Damage Associated With Myocardial Infarction
    U-1176 Treatment Or Prevention Of Stroke
    U-1177 Reduction Of Cardiac Tissue Damage Associated With Myocardial Infarction
    U-1178 Relief Of Moderate To Severe Chronic Pain
    U-1179 Treatment Of A Cancer Mediated By An Anaplastic Lymphoma Kinase (Alk)
    U-118 Method Of Lowering Blood Sugar Level
    U-1180 Treatment Of The Following Infections: Complicated Skin And Skin Structure Infections And Staphylococcus Aureus Bloodstream Infections (Bacteremia) Including Those With Right-Sided Infective Endocarditis
    U-1181 A Method Of Treating Or Preventing Ocular Pain In A Patient
    U-1182 Treatment Of Cyclic Heavy Menstrual Bleeding
    U-1183 A Method For Administering Follicle Stimulating Hormone (Fsh) For Ovarian Follicle Or Testicular Stimulation In The Human
    U-1184 Treatment Of Erectile Dysfunction And The Signs And Symptoms Of Benign Prostatic Hyperplasia
    U-1185 Treatment Of Opioid-Induced Constipation
    U-1186 Administration Of An Inhalable Powder Comprising Tiotropium Via Device
    U-1187 Treatment Of Pathological State By Antagonizing Bradykinin Receptor Including Treatment Of Acute Attacks Of Hereditary Angioedema (Hae)
    U-1188 Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate
    U-1189 Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With Metformin
    U-119 Treatment Of Nasal Hypersecretion
    U-1190 Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With Insulin
    U-1191 Method Of Tx Type 2 Dm In Pts For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combo With An Agent Acting On An Atp-Dependent Channel In Beta Cells Such As A Sulfyonylurea(Incl Glipizide, Glimepiriide & Glyburide)
    U-1192 Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With A Sulfonylurea (Such As Glipizide, Glimepiride And Glyburide)
    U-1193 Method Of Treating Type 2 Diabetes Melitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With A Ppar-Gamma Agonist (Such As Pioglitazone And Rosiglitazone)
    U-1194 Method For Treating Insomnia
    U-1195 Prevention And Treatment Of Secondary Hyperparathyroidism Associated With Chronic Kidney Disease (Ckd) Stage 5, Which May Result In Renal Osteodystrophy, While Avoiding Hyperphosphatemia
    U-1196 Relief Of Signs And Symptoms Of Rheumatoid Arthritis And Osteoarthritis And To Decrease Risk Of Developing Upper Gastrointestinal Ulcers In Patients Who Are Taking Ibuprofen For Those Indications
    U-1197 Method Of Treatment Of Children With Central Precocious Puberty
    U-1198 Rectiv Is A Nitrate Vasodilator Indicated For The Treatment Of Moderate To Severe Pain Associated With Chronic Anal Fissure
    U-1199 Treatment And Prevention Of Postmenopausal Or Glucocorticoid-Induced Osteoporosis And Treatment To Increase Bone Mass In Men With Osteoporosis
    U-12 Method Of Treating [A] Human Suffering From Depression
    U-120 Controlling Or Preventing Post-Operative Intraocular Pressure Rises Associated With Ophthalmic Laser Surgical Procedures
    U-1200 Reducing The Risk Of Stroke And Systemic Embolism
    U-1201 For The Treatment Of Intermediate Or High-Risk Myelofibrosis
    U-1202 Method For Relieving Or Treating Constipation In A Patient With Irritable Bowel Syndrome
    U-1203 Method For Relieving Or Treating Constipation In A Human Constipated Patient
    U-1204 Treatment Of Uveitis
    U-1205 Treatment Of Macular Edema
    U-1206 Delivering An Ocular Implant As Described In The Dosage And Administration Section Of The Approved Labeling Of Ozurdex
    U-1207 Infant Use Aged 1 Month To Less Than One Year, Gerd And Erosive Esophagitis
    U-1208 Treatment Of Hypotrichosis Of The Eyelashes By Increasing Their Growth Including Length, Thickness And Darkness
    U-1209 Treatment Of Human Immunodeficiency Virus (Hiv) Infection In Adult Patients, And Treatment Of Human Immunodeficiency Virus (Hiv) Infection In Pediatric Patients 3 Years Of Age And Older
    U-121 Method Of Treating Conditions Mediated Through Histamine H2-Receptors
    U-1210 Use Of Revlimid (Lenalidomide) While Preventing The Exposure Of A Fetus Or Other Contraindicated Individual To Revlimid (Lenalidomide)
    U-1211 Use Of Revlimid (Lenalidomide) To Inhibit The Secretion Of Pro-Inflammatory Cytokines, Including Tumor Necrosis Factor Alpha
    U-1212 Use Of Revlimid (Lenalidomide) For The Treatment Of Multiple Myeloma And Transfusion-Dependent Anemia In Myelodysplastic Syndromes (Mds)
    U-1213 Topical Treatment Of Seborrheic Dermatitis In Immunocompetetent Patients 12 Years Of Age And Older
    U-1214 Methof For Relieving Constipation In A Human Patient That Comprises Administering To The Patient A Dosage Unit Comprising (I) 24mcg+/- 10% Of A Drug Substance And (Ii) A Pharmaceutically Suitable Excipient
    U-1215 Use Of Revlimid (Lenalidomide) For The Treatment Of Transfusion-Dependent Anemia In Myelodysplastic Syndromes (Mds)
    U-1216 Use Of Revlimid (Lenalidomide) For The Treatment Of Multiple Myeloma
    U-1217 Method Of Increasing Hair Growth
    U-1218 Method Of Stimulating Hair Growth
    U-1219 Method Of Increasing The Number Of Hairs
    U-122 A Therapeutic Method For Controlling Thrombosis
    U-1220 Treatment Of Renal Cell Carcinoma
    U-1221 To Stimulate The Immune System To Induce T Cell Proliferation
    U-1222 To Inhibit The Proliferative Activity Of Neoplastic Cells
    U-1223 Method For Treating Type 2 Diabetes Using A Sustained-Release Composition Containing Exenatide
    U-1224 Reductions In Body Weight Are Observed With Exenatide
    U-1225 Accelerating The Time To Upper And Lower Gastrointestinal Recovery Following Partial Large Or Small Bowel Resection Surgery With Primary Anastomosis
    U-1226 A Method Of Providing A Predetermined Concentration Of Nitric Oxide To A Patient
    U-1227 Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Metformin Hcl Extended Release Is Appropriate
    U-1228 Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Metformin Hcl Extended Release Is Appropriate Alone Or In Combination With Insulin
    U-1229 Treatment Of Mildly To Moderately Active Ulcerative Colitis In Male Patients
    U-123 Method For Controlling Thrombosis And Decreasing Blood Hypercoagulation And Hemorrhaging Risks
    U-1230 A Method Of Providing Nitric Oxide Therapy To A Patient
    U-1231 Treatment Of Moderate-To-Severe Primary Restless Leg Syndrome In Adults
    U-1232 Use As Anticoagulant In Pts W/ Unstable Angina Undergoing Ptca; W/ Provisional Use Of Glycoprotein Iib/Iiia Inhibitor, As Anticoagulant In Pts Undergoing Pci And For Pts W/, Or At Risk Of, Hit/Hitts Undergoing Pci.Intented For Use W/Aspirin
    U-1233 Treatment Of Chronic Hepatitis C (Chc) Genotype 1 Infection, Administered With Food
    U-1234 For Reducing Total Cholesterol (Total-C), Ldl-C, Apo-Lipoprotein B, Or Total Triglycerides, And Treating Hypertriglyceridemia
    U-1235 Reduction Of Elevated Intraocular Pressure In Patients With Glaucoma Or Ocular Hypertension
    U-1236 Use Of Thalomid (Thalidomide) For The Treatment Of Multiple Myeloma
    U-1237 Combo W/ Other Antiretrovirals For Tx Of Hiv-1 In Antiretroviral Tx-Experienced Pt 6 Years Up, Who Have Evidence Of Viral Replication And Hiv-1 Strains Resistant To Non-Nucleoside Reverse Transcriptase Inhibitor And Other Antiretrovirals
    U-1238 Treatment Of Anemia Due To Chronic Kidney Disease
    U-1239 Magnetic Resonance Imaging Of The Liver
    U-124 Treatment Of Acne
    U-1240 Treatment Of Heavy Menstrual Bleeding In Women Without Organic Pathology Who Choose To Use An Oral Contraceptive As Their Method Of Contraception
    U-1241 Management Of Moderate To Severe Pain By Orally Administering An Intact Composition As Claimed
    U-1242 Prevention Of Respiratory Distress (Rds) In Premature Infants
    U-1243 With Dry Hands, Gently Remove The Suprenza (Phentermine Hydrochloride Odt) Tablet From The Bottle. Immediately Place The Suprenza Tablet On Top Of The Tongue Where It Will Dissolve, Then Swallow With Or Without Water
    U-1244 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Sulfonlyurea
    U-1245 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Pioglitazone
    U-1246 Single Dose Administration Into The Surgical Site To Produce Postsurgical Analgesia
    U-1247 Management Of Postherpetic Neuralgia (Phn) In Adults
    U-1248 Use Of Topical Diclofenac On The Knee And A Second Topical Medication On The Same Knee
    U-1249 Treatment Of Male Patient Having A Disease Or Condition Responsive To A Teratogenic Drug
    U-125 Treatment Neurogenerative Diseases
    U-1250 Treatment Of Pain, Including Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Or Spinal Cord Injury, Postherpetic Neuralgia, And Fibromyalgia
    U-1251 A Method Of Controlling Postoperative Ocular Pain And Burning/Stinging In A Patient
    U-1252 Method For Chronic Weight Management By Decreasing Food Intake
    U-1253 Method For Chronic Weight Management By Inducing Satiety
    U-1254 Method For Chronic Wieght Management By Controlling Weight Gain
    U-1255 Method For Chronic Weight Management By Treating Obesity
    U-1256 Treatment Of Seborrheic Dermatitis
    U-1257 Treatment Of Ophthalmic Disorders
    U-1258 Visualization During Vitrectomy Procedures
    U-1259 Prophylaxis Of Hiv-1 Infection
    U-126 Treatment Of Gastritis
    U-1260 Treatment Of Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies Including Bortezomib And An Immunomodulatory Agent And Have Demonstrated Disease Progression On Or Within 60 Days Of Completion Of The Last Therapy
    U-1261 Reduction Of The Risk Of Hospitalization For Atrial Fibrillation
    U-1262 Use Of Qsymia (Phentermine And Topiramate) For Weight Management, Including, But Not Limited To Effecting Weight Loss, Treating Obesity, And/Or Treating Overweight
    U-1263 Treatment Of Chronic Obstructive Pulmonary Disease (Copd) Or Chronic Bronchitis
    U-1264 Treatment Of A Respiratory Disease
    U-1265 Patented Method Of Using Repaglinide In Combination With Metformin As Indicated For Improving Glycemic Control In Adults With Type 2 Diabetes Mellitus
    U-1266 Method Of Treating Middle-Of-The-Night Insomnia
    U-1267 Treatment Of Rheumatoid Arthritis By Delayed Release Formulation Of 1mg Or 2mg Of Prednisone
    U-1268 Treatment Of Pulmonary, Gastrointestinal And/Or Rheumatological Diseases Or Conditions By Use Of Delayed Release Formulations Of 1mg Or 2mg Prednisone
    U-1269 Treatment Of Rheumatologic, Allergic, Pulmonary, Gastrointestinal, Dermatologic Diseases Or Conditions By The Use Of A Delayed Release 5mg Prednisone Tablet
    U-127 Method Of Producing Neuromuscular Blockade
    U-1270 Method Of Treating Type 2 Diabetes Mellitus By Administering Linagliptin In Combination With Insulin (With Or Without Metformin And/Or Pioglitazone)
    U-128 Method For Treatment Of Tumors
    U-129 Method To Destroy Or Impair Target Cells
    U-13 A Method For Treating Anxiety In A Human Subject In Need Of Such Treatment
    U-130 Management Of Patients With Mastocytosis
    U-131 Photodamaged Skin
    U-132 Inhibiting Hiv Protease
    U-133 Management Of Obesity Including Weight Loss And Maintenance In Patients On A Reduced-Calorie Diet
    U-134 Treatment Of Acne Vulgaris
    U-135 Antitumor Agent
    U-136 Process For Waste Nitrogen Removal
    U-137 Method Of Treating Bacterial Vaginosis
    U-138 Treatment Of Allergic Rhinitis
    U-139 Treatment Of Allergic Reactions
    U-14 Adjunctive Therapy For The Prevention And Treatment Of Hyperammonemia In The Chronic Management Of Patients With Urea Cycle Enzymopathies
    U-140 Use Of Norvir To Inhibit Hiv Protease Or To Inhibit An Hiv Infection
    U-141 Treatment Of Ulcerative Colitis
    U-142 Method Of Treating Allergic Reactions In A Mammal By Using This Active Metabolite
    U-143 Biodegradable Superparamagnetic Metal Oxides As Contrast Agents For Mr Imaging
    U-144 Biologically Degradable Superparamagnetic Materials For Use In Clinical Applications
    U-145 Biologically Degradable Superparamagnetic Particles For Use As Nuclear Magnetic Resonance Imaging Agents
    U-146 Method Of Treating Susceptible Neoplasms In Mammals
    U-147 Detection Of Gastrointestinal Disorders And The Subsequent Breath Collection And Measurement Of 13co2
    U-148 Device For Collecting A Breath Sample
    U-149 Method Of Treating An Animal, Including A Human Suffering From Or Susceptible To Psychosis, Acute Mania Or Mild Anxiety States
    U-15 Method Of Lowering Intraocular Pressure
    U-150 Method Of Use For Controlling Hyperglycemia By Administration Of This Sustained Release Dosage Form Of Glipizide
    U-151 Relief Of Symptoms Of The Common Cold
    U-152 Method Of Treating Anxiety Related Disorders Including Obsessive Compulsive Disorder
    U-153 Treatment Of Initial Episode Genital Herpes
    U-154 Method Of Treating Animals Suffering From An Appetite Disorder
    U-155 Treatment Of Erectile Dysfunction
    U-156 Method Of Providing Anesthesia
    U-157 Treatment Of A Human Suffering From Vitamin B12 Deficiency
    U-158 Angina
    U-159 Treatment Of Interstitial Cystitis
    U-16 Use In Lung Scanning Procedures
    U-160 Treatment Of Bacterial Infectious Disease
    U-161 Method Of Inhibiting Cholesterol Biosynthesis In A Patient
    U-162 Method Of Use To Inhibit Cholesterol Synthesis In A Human Suffering From Hypercholesterolemia
    U-163 Method Of Using Troglitazone To Treat Impaired Glucose Tolerance To Prevent Or Delay The Onset Of Noninsulin-Dependent Diabetes Mellitus
    U-164 Method Of Using Troglitazone To Prevent Or Delay The Onset Of Noninsulin-Dependent Diabetes Mellitus In A Defined Population Of Patients
    U-165 Treatment Of Symptomatic Benign Prostatic Hyperplasia
    U-166 Treatment Of H.Pylori-Associated Duodenal Ulcer
    U-167 Method For Treating Hiv-1 Infection
    U-168 Method Of Inhibiting Lipoxygenase Activity In A Mammal Which Is The Mode Of Action In The Treatment Of Asthma
    U-169 Methods Of Using The Compound/Drug Product As A Contrast Agent In Magnetic Resonance Imaging
    U-17 Treatment Of Ventricular And Supraventricular Arrhythmias
    U-170 Method Of Obtaining An Mr Image Using The Composition/Drug Product As A Contrast Agent
    U-171 Methods Of Using The Compound/Drug Product As An Oral Contrast Agent In Magnetic Resonance Imaging Of The Gastrointestinal Tract
    U-172 Treatment Of Genital Warts
    U-173 Administration To A Host Suffering From Gestational Diabetes
    U-174 Use As An Antihistamine Agent
    U-175 Method Of Treating Malignant Tumors
    U-176 Method Of Treating A Patient Suffering From Listed Conditions, Including Specific Psychoses
    U-177 Fungicide
    U-178 Facilitated Adherence Of Agents To Skin
    U-179 Enhanced Cutaneous Penetration Of A Dermally-Applied Pharmacologically Active Agent
    U-18 Method For Inhibiting Gastric Secretion In Mammals
    U-180 Treatment Of Adult And Pediatric Patients (Over 6 Months Of Age) With Advanced Hiv Infection
    U-181 Producing Alpha Adrenergic Antagonistic Action In A Host
    U-182 Use Of Salmeterol In Patients With Reversible Airway Obstruction
    U-183 Treatment Of Conditions Caused By Disturbance Of Neuronal 5ht Function
    U-184 Treating Allergic Eye Diseases In Humans
    U-185 Method Of Treating Hypertension
    U-186 Method For Treating Gi Disorders Caused By H.Rylori Which Comprises Administration Of Ranitidine Bismuth Citrate And Clarithromycin For A Greater Than Additive Effect
    U-187 Therapeutic Treatment Of Calcific Tumors
    U-188 Treatment Of H.Pylori Associated Duodenal Ulcer
    U-189 Enhancement Of The Bioavailability Of The Drug Substance
    U-19 Treatment Of Inflammation
    U-190 Use Of Ritonavir In Combination With Any Reverse Transcriptase Inhibitor
    U-191 Method Of Treatment For Controlling And Lowering Intraocular Pressure In A Human
    U-192 Use In Treating Allergic Reactions
    U-193 Psoriasis
    U-194 Treating Angina Pectoris And High Blood Pressure
    U-195 Method For The Diagnosis Of Gastrointestinal Disorders By Urea Isotoac Or Nitrogen Labeled Carbon
    U-196 Treatment Of Metastatic Breast Cancer In Postmenopausal Women With Estrogen Receptor Positive Tumors
    U-197 Use In Combination With Certain Lhrh Analogues For The Treatment Of Advanced Prostate Cancer
    U-198 Treatment Metastatic Carcinoma Of Ovary After 1st Line Failure Or Subsquent Chemotherapy, Treatment Of Breast Cancer After Failure Of Combination Chemotherapy For Metastatic Disease And 2nd Line Treatment Of Aids Related Kaposi's Sarcoma
    U-199 Method Of Treating Infectious Upper Gi Tract Disorders Caused By Campylobacter Pyloridis Infection Comprising Administration Of A Bismuth Agent And An Antimicrobial Agent
    U-2 Treatment Or Prophylaxis Of Angina Pectoris And Arrhythmia
    U-20 A Process For Treating A Patient Suffering From Parkinson's Syndrome And In Need Of Treatment
    U-200 Method Of Treating Gi Disorders Comprising Administration Of A Bismuth-Containing Agent And H2 Receptor Blocking Anti-Secretory Agent
    U-201 Method Of Treating Gi Disorders Comprising Administration Of Campylobacter-Inhibiting Antimicrobial Agent And H2 Receptor Blocking Anti-Secretory Agent
    U-202 Method Of Treating Peptic Ulcer Disease Caused By Campylobacter Pyloridis Comprising Oral Administration Of 50 To 5,000mg Bismuth Daily For 3-56 Days
    U-203 Treatment Of Advanced Breast Cancer In Postmenopausal Women With Disease Progression Following Antiestrogen Therapy
    U-204 Use Of Taxol In Combination With G-Csf For Treatment Of Patients With Aids-Related Kaposi's Sarcoma
    U-205 Method For Treating Heartburn
    U-206 Method Of Using Fsh Alone, Without The Presence Of Exogeneous Lh, In In Vitro Fertilization
    U-207 Use As Nasal Spray
    U-208 Vaginal Administration Using Specified Formulation
    U-209 Vaginal Administration Of Progesterone Using Specified Formulation
    U-21 Treatment Of Humans Suffering Undesired Urotoxic Side Effects Caused By Cytostatically Active Alkylating Agents
    U-210 Method Of Treating Congestive Heart Failure
    U-211 Use In Patients With Reversible Airway Obstruction
    U-212 Method Of Treatment Of Parkinson's Disease
    U-213 Method Of Inhibiting Cholesterol Biosynthesis And Treating Hypercholesterolemia And Method For Treating Hyperlipidemia
    U-214 Use As A Blood Glucose-Lowering Agent
    U-215 Treatment Of Epilepsy Twice Daily. Treating A Patient By Administering Carbamazepine In A Dosage Form Capable Of Maintaining Blood Concentration From 4-12mcg/Ml Over 12 Hours
    U-216 Treatment Of Adenocarcinoma, Including Stage B2-C By Administering An Agonist Of Lh-Rh And Flutamide
    U-217 Method Of Producing Anesthesia
    U-218 Method For Limiting The Potential For Microbial Growth In The Drug Product
    U-219 Treatment Of Parkinson's Disease
    U-22 Method Of Combatting Pathologically Reduced Cerebral Functions And Performance Weaknesses, Cerebral Insufficiency And Disorders In Cerebral Circulation And Metabolism In Warm-Blooded Animals
    U-220 Method Of Diagnosis
    U-221 Selective Vasodilation By Continuous Adenosine Infusion
    U-222 Method Of Treating Paget's Disease Using Actonel
    U-223 Treatment Of Bacterial Conjunctivitis Caused By Susceptible Strains Of Microorganisms
    U-224 Controlling Intraocular Pressure
    U-225 Method For Delivery
    U-226 Method Of Enhancing The Dissolution Profile Of A Pharmaceutical From A Solid Dosage Form Containing The Pharmaceutical And Simethicone
    U-227 Nasal Administration
    U-228 Asthma
    U-229 Cardiac Insufficiency (Congestive Heart Failure)
    U-23 Method For Treating Prostatic Carcinoma Comprising Administering Flutamide
    U-230 Prevention Of Acute Cardiac Ischemic Events
    U-231 Use In Parkinson's Disease
    U-232 Method Of Treating Migraine
    U-233 Decreasing Mortality Caused By Congestive Heart Failure
    U-234 Method Of Using Ribavirin To Treat Viral Infections In Mammals
    U-235 Method Of Modulating Th1 And Th2 Response In Activated T Cells Of A Human Comprising Administering Ribavirin To The T Cells In A Dosage Which Promotes The Th1 Response And Suppresses The Th2 Response
    U-236 Treating Male Pattern Baldness With 0.05 To 3.0mg/Day
    U-237 Method Of Performing Nmr Imaging With A Patient Comprising Administering To The Patient An Effective Amount Of Contrast Agent Disclosed In The Claims
    U-238 Imaging A Body Tissue And Subjecting To Nmr Tomography, Administering An Amount Of Pharmaceutical Agent For Affecting The Relaxation Times Of Atoms In Body Tissues Undergoing Nmr Diagnosis, Whereby The Image Contrast In Enhanced....
    U-239 Treating Or Controlling Ocular Inflamation Which Comprises Topically Administering To Affected Eye A Composition Comprising An Nsaid, A Polymeric Quaternary Ammonium Compound And Boric Acid
    U-24 Method For Treating Prostate Adenocarcinoma Comprising Administering An Antiandrogen Including Flutamide And An Lhrh Agonist
    U-240 Treatment Of Acute Migraine Attacks
    U-241 For Short-Term Treatment Active Duodenal Ulcer, Maintenance Therapy For Duodenal Ulcer Patients At Reduced Dosage After Healing Of Active Ulcer, Short-Term Treatment Active Benign Gastric Ulcer & Gerd, Pathological Hypersecretory Conditions
    U-242 Use Of Follitropin Alpha Alone In In-Vitro Fertilization
    U-243 Topical Administration
    U-244 Platelet Aggregation Inhibitors
    U-245 Treatment Of Seborrhea Dermatitis In Humans
    U-246 Phosphate Binding
    U-247 Treatment Of Rheumatoid Arthritis
    U-248 Treatment Of Hiv
    U-249 Method Of Treating Allergic Or Non-Allergic Rhinitis In Patients By Administering Aerosolized Particles Of Mometasone Furoate
    U-25 Reducing Cholesterol In Cholelithiasis Patients
    U-250 Treatment Of Hepatitis B Infection
    U-251 Use Of Troglitazone In Combination With Sulfonylureas In The Treatment Of Type Ii Diabetes
    U-252 Method Of Treating A Human Subject Having Gaucher's Disease
    U-253 Oral Transmucosal Use
    U-254 Use Of Aggrastat In Combination With Heparin
    U-255 Improved Wakefulness In Patients With Excessive Daytime Sleepiness Associated With Narcolepsy
    U-256 Treatment Of Hiv Infection In Combination With One Or More Additional Hiv Antiviral Agents
    U-257 Treatment Of Hiv Infection
    U-258 Treatment Of Neurodegenerative Diseases
    U-259 Treatment Of Androgenic Alopecia By Oral Administration Drug Substance
    U-26 Reducing Cholesterol Gallstones And/Or Fragments Thereof
    U-260 Reduction Of Intraocular Pressure In Patients With Open Angle Glaucoma And Ocular Hypertension Who Are Intolerant Of Other Iop Lowering Medications Or Insufficiently Responsive To Another Iop Lowering Medication
    U-261 Treating Benign Prostatic Hyperplasia With A Genus Of Compounds, Including Finasteride
    U-262 Treating Benign Prostatic Hypertrophy With Finasteride
    U-263 Method Of Treating A Malignant Condition Through Intravascular Administration Of Busulfan. Method For Treating Leukemia Or Lymphoma In A Patient Undergoing A Bone Marrow Transplant Through Intravenous Administration Of Busulfan
    U-264 Method Of Treating A Malignant Disease Through Parenteral Administration Of Busulfan. Method For Treating A Patient Undergoing A Bone Marrow Transplant Through Intravascular Administration Of Busulfan
    U-265 Use As Laxative
    U-266 Relief Of The Signs And Symptoms Of Osteoarthritis; Relief Of The Signs And Symptoms Of Rheumatoid Arthritis In Adults; Management Of Acute Pain In Adults; Treatment Of Primary Dysmennorrhea; Acute Treatment Of Migraine Attacks In Adults
    U-267 Preventing Heartburn Episodes Following Ingestion Of Heartburn-Inducing Food/Beverage, Comprising Admin To Pt, 30 Min Prior To Consumption By The Pt The Food/Beverage, A Composition Comprising 10mg Famotidine
    U-268 Acromegaly
    U-269 Excess Gh-Secretion Or Gastro-Intestinal Disorders
    U-27 Dissolving Cholesterol Gallstones And/Or Fragments Thereof
    U-270 Method Of Improving The Time For Administration Or The Time Between Changes Of Giving Sets For The Drug Product
    U-271 Method Of Treating Tumors
    U-272 Method Of Treating Carcinoma
    U-273 Cutaneous T-Cell Lymphoma
    U-274 Zanamivir For Inhalation
    U-275 Method Of Use Of The Drug Substance
    U-276 Method Of Use Of Levobupivacaine
    U-277 Neurological And Other Disorders (Treatment Of Epilepsy, Bid Oral Dosing)
    U-278 Method Of Use Of The Indication Of The Drug Product
    U-279 Method Of Use Of The Approved Product
    U-28 Cerebral, Coronary, Peripheral, Visceral And Renal Arteriography, Aortography And Left Ventriculography
    U-280 Treating Precipitated Acute Urinary Retention With Finasteride
    U-281 Antimycotic Uses, Specifically Treatment Of Onychomycosis
    U-282 Method Of Treating Bacterial Infections
    U-283 Method For Treating Menopausal Symptoms In A Postmenopausal Female
    U-284 Menopausal And Postmenopausal Disorders (Including Vasomotor Symptoms Associated With Menopause, And Vulvar And Vaginal Atrophy) And Osteoporosis
    U-285 Depression And Social Anxiety Disorder/Social Phobia
    U-286 Depression
    U-287 Treatment Or Prevention Of Osteoporosis
    U-288 Therapy Of Influenza
    U-289 Treatment Of Non-Hyperkeratotic Actinic Keratoses Of Face And Scalp
    U-29 Ct Imaging Of The Head And Body, And Intravenous Excretory Urography
    U-290 Inhibiting Transplant Rejection Using Rapamycin (Sirolimus)
    U-291 Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) In Combination With Cyclosporin
    U-292 Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) In Combination With Azathioprine
    U-293 Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) In Combination With A Corticosteroid
    U-294 Treatment Of Hyperpigmentary Disorders
    U-295 Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms
    U-296 Treating Migraine Pain And One Or More Of A Cluster Of Symptoms Characteristic Of A Migraine Attack Symptoms Being Selected From Photophobia, Phonophobia Nausea And Functional Disability
    U-297 Prevention Or Treatment Of Reversible Vasoconstriction By The Inhalation Of Nitric Oxide With An Oxygen Containing Gas
    U-298 Method Of Combating Bacteria In A Patient
    U-299 Treatment Of Adenomatous Polyps
    U-3 Treatment Of Hypertension
    U-30 Cerebral Angiography, And Venography
    U-300 Indicated For The Reduction Of Elevated Total And Ldl Cholesterol Levels In Patients With Primary Hypercholesterolemia
    U-301 Use Of Troglitazone In Combination With Sulfonylureas And Biguanides In The Treatment Of Type Ii Diabetes
    U-302 To Reduce The Risk Of Stroke In Patients Who Have Had Transient Ischemia Of The Brain Or Completed Ischemic Stroke Due To Thrombosis
    U-303 Method Of Use Patent-Product Approved For Treatment Of Osteoporosis, Paget's Disease, Prevention And Treatment Of Glucocorticoid Induced Osteoporosis
    U-304 A Method Of Treatment Of A Condition Involving An Antibody Antigen Reaction
    U-305 Methods For Using The Drug Product
    U-306 Treatment Of Post-Menopausal Urogenital Symptoms Associated With Estrogen Deficiency
    U-307 Claims An Olanzapine Polymorph Useful For Treating Any Number Of Listed Conditions, Including Specific Psychoses,Employing Olanzapine As Per The Indication Of This Nda
    U-308 Claims A Solid Oral Formulation Including Tablets And Granules Of Olanzapine Useful For Treating Any Number Of Listed Conditions, Including Specific Psycholes, Employing Olanzapine As Per The Indications Of This Nda
    U-309 Treating Sjoegren Syndrome
    U-31 Intra-Arterial Digital Subtraction Angiography
    U-310 Treatment Of Xerostomia
    U-311 Hormone Replacement
    U-312 Panic Disorder, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder
    U-313 Treatment Of Congestive Heart Failure
    U-314 Method For Treating Hyperparathyroidism Which Comprises Suppressing Parathyroid Activity
    U-315 Method For Administering Drug To Gastrointestinal Tract
    U-316 Method Of Treating A Subject Suffering From Prostate Cancer
    U-317 Method Of Using Troglitazone To Treat Patients Having Insulin Resistance
    U-318 Treatment Of Patients With An Overactive Bladder With Symptoms Of Urinary Frequency, Urgency, Or Urge Incontinence
    U-319 Treatment Of Microbial Infections
    U-32 Palliative Treatment Of Patients With Ovarian Carcinoma Recurrent After Prior Chemotherapy, Including Patients Who Have Been Previously Treated With Cisplatin
    U-320 Inhibiting Or Eliminating Acute Myeloid Leukemia
    U-321 Reduction Of Elevated Ipth Levels In The Mgt Of Secondary Hyperparathyroidism In Patients Undergong Chronic Renal Dialysis
    U-322 Treatment Of Alzheimer's Dementia
    U-323 Use As A Bile Acid Sequestrant
    U-324 Method Of Treating An Animal, Including A Human, Suffering From Or Susceptible To Psychosis Or Acute Mania Employing Olanzapine
    U-325 Method Of Treating A Patient Suffering From Any Of A Number Of Listed Conditions, Including “Bipolar Disorder Nos“ Employing Olanzapine
    U-326 Method Of Treating Schizophrenia And Bipolar Disorder
    U-327 Method Of Treating A Patient Suffering From Any Of A Number Of Listed Psychotic Conditons Employing Olanzapine
    U-328 Method Of Treating A Patient Suffering From Any Of A Number Of Listed Conditions Including “A Psychotic Condition“ Employing An Olanzapine Polymorph
    U-329 Use Of Avandia As Monotherapy, In Combination With Metformin, And In Combination With Sulfonylureas To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus
    U-33 Treating Viral Infections In A Mammal
    U-330 Treatment Of Nausea And Vomiting
    U-331 Method Of Treating Hyperlipidemia With Nicotinic Acid By Dosing Once Per Day In The Evening Or At Night
    U-332 Treatment Or Prevention Of Bronchospasm
    U-333 Method Of Treating Ocular Hypertension
    U-334 Treatment Of Excessive Female Facial Hair
    U-335 Use Of Pravastatin Sodium For Secondary Prevention Of Coronary Events In Men And Women Who Have Had A Myocardial Infarction And Have Normal Cholesterol Levels
    U-336 Diagnostic Radioimaging
    U-337 Use Of Cardiolite/Miraluma Kit For The Preparation Of Tc99m Sestamibi
    U-338 Methods For Treating Disturbances Of Mood, Disturbances Of Appetite, Depressed Mood, Or Carbohydrate Craving All Associated With Premenstrual Syndrome
    U-339 Prevention Of Cardio-Toxicity Caused By The Administration Of Doxorubicin
    U-34 Treating Viral Infections In A Warm-Blooded Animal
    U-340 The Long Term Treatment Of Growth Failure Due To Lack Of Adequate Endogenous Growth Hormone Secretion In Children
    U-341 Method For Enhancing The Treatment Of ... Late Luteal Phase Dysphoric Disorder
    U-342 Method For Treatment Of Late Luteal Phase Dysphoric Disorder
    U-343 Reduction Of Intestinal Gas, Cramping And Anorectal Irritation
    U-344 Method For Inhibiting Hiv Infection By Administering Ritonavir In Combination With Another Hiv Protease Inhibitor
    U-345 Ritonavir And Another Hiv Protease Inhibitor For Concomitant Administration For The Treatment Of An Hiv Infection
    U-346 Method For Inhibiting Cytochrome P450 Monooxygenase With Ritonavir And A Method For Improving The Pharmcokinetics Of A Drug That Is Mtabolized By Cytochrome P450 Monooxygenase By Admin The Drug And Ritonavir
    U-347 Method Of Use In Combination With Reverse Transcriptase Inhibitors
    U-348 Method Of Use For Inhibiting Hiv Infection
    U-349 Method Of Use Which Is Subject Of The Application
    U-35 Treating Cytomegalovirus In A Human With An Injectable Composition
    U-350 Preparation Of A Pharmaceutical Composition For Concomitant Admin With A Reverse Transcriptase Inhibitor
    U-351 Inhibiting Protease With Lopinavir And Inhibiting An Hiv Infection With Lopinaviir
    U-352 Inhibiting Hiv Infection By Administering Ritonavir In Combination With A Reverse Transcriptase Inhibitor
    U-353 Prevention And Treatment Of Osteoporosis
    U-354 Method Of Treating Hyperlipidemia With Nicotinic Acid Without Causing Treatment-Limiting Elevations In Uric Acid Or Glucose Levels Or Causing Liver Damage, By Dosing Once Per Day In The Evening Or At Night
    U-355 Method Of Assisting Person To Quit Smoking...Transdermally Admin Nicotine Via..Patch Adhered To Skin At Dosing Rate Approx Same As Absorbed From Smoking
    U-356 Delivering A Medicinal Aerosol Formulation Using Cfc-Free Propellant 134a.
    U-357 Use Of The Drug Product In Photodynamic Therapeutic Protocols For The Treatment Of Age-Related Macular Degeneration And Related Conditions Involving Unwanted Neovasculature In The Eye
    U-358 Depression, Obsessive Compulsive Disorder, Panic Disorder And Social Anxiety Disorder
    U-359 Method Of Use Of Visicol
    U-36 Methods Of Treating Bacterial Illnesses
    U-360 Method Of Treating A Patient Suffering From Any Of A Number Of Pathological Psychological Conditions Including Mental Disorders Employing Olanzapine As Per The Indication Which Is The Subject Matter Of This Snda-011
    U-361 Management Of Anxiety Disorders And The Short-Term Relief Of The Symptoms Of Anxiety
    U-362 Use Of Approved Formulations To Treat All Approved Disease Indications
    U-363 Method Of Treating A Patient Suffering From Any Of A Number Of Pathological Psychological Conditions That Relate To The Use Of A Psychoactive Substance Employing Olanzapine As Per The Indication The Subject Matter Of Supplement 011
    U-364 Treating A Patient Suffering From Or Susceptible To Any Number Of Listed Conditions Including Psychosis, Employing Olanzapine As Per The Indication Which Is The Subject Matter Of This Snda-011
    U-365 Method For The Treatment Of Cardiovascular Disease Through The Administration Of A Calcium Blocking Vasodilator In Our Extended, Controlled Release Formulation
    U-366 Method For The Treatment Of Cardiovascular Disease Through The Administration Of A Calcium Blocking Vasodilator In A Delayed Release Formulation
    U-367 Treatment Of Cardiovascular Disorders
    U-368 Heartburn
    U-369 Method Of Controlling And Lowering Intraocular Pressure
    U-37 Method Of Treating Gastrointestinal Disease
    U-370 Intravaginal Treatment Of Vaginal Infections With Buffered Metronidazole Compositions
    U-371 Approval For Marketing Only Under A Special Restriction Program Approved By Fda Called “System For Thalidomide Education And Prescribing Safety“ (S.T.E.P.S.)
    U-372 Method For Administering A Beneficial Drug To The Gi Tract Of An Animal, Which Method Comprises Admitting An Osmotic Device Orally Into The Animal...
    U-373 General Use Claim Submitted For 12 Nexium Patients Stating “Pertinent To The Capsule Formulation For Nexium And Its Indications For The Treatment Of Gerd And Eradication Of H.Pylori To Reduce The Risk Of Duodenal Ulcer Recurrence
    U-374 Kit Adapted And Designed To Provide Both Data On The Current Reproductive Status Of A Patient And Contraception For Those Who Are Not Pregnant, But Recently Engaged In Unprotected Sex
    U-375 Method Of Using Ribavirin For Treating A Disease Responsive To Ribavirin, E.G. Hepatitis C
    U-376 Treatment Of Influenza
    U-377 Method Of Treating Pt With Chronic Hepatitis C Having Hcv Genotype 1 And Viral Load Greater Than 2 Million Copies/Ml To Eradicate Detectable Hcv-Rna By Admin Combination Of Ribavirin And Interferon Alfa-2b For A Least 24 Weeks
    U-378 Method For Treating Incontinence
    U-379 Method Of Treating Onychromycosis
    U-38 Treatment Of Paroxysmal Supraventricular Tachycardia
    U-380 Combinations Of Taxol (Paclitaxel) And Cisplatin Which Are Suitable For The Treatment Of Ovarian And Non-Small Cell Lung Carcinomas
    U-381 Treatment Of Hyperphosphatemia
    U-382 Method Of Stablizing Prostaglandin
    U-383 Method For Treating Glaucoma And Ocular Hypertension
    U-384 Treatment Of Cmv Retinitis
    U-385 Treatment Of Peptic Ulcers
    U-386 Treatment Of Patients Suffering From A Late Asthmatic Reaction Or Late Phase Asthma
    U-387 Treatment Of Patients With Respiratory Disorders
    U-388 Smoking Cessation Aid Applied To The Skin
    U-389 Smoking Cessation Aid Applied To The Skin On Waking And Removed Prior To Sleep After About 16 Hours
    U-39 Angina Pectoris
    U-390 Method Of Using The Drug To Treat Neuroimmunologic Diseases (Including Multiple Sclerosis)
    U-391 Use Of Casodex In Combination With Lhrh Agonists For The Treatment Of Prostate Cancer
    U-392 Treatment Of Patients For Inflammation
    U-393 Management Of Incontinence, Mgt Of Hormone Replacement Therapy, Treatment Of Involuntary Incontinence, Mgt Overactive Bladder And Increasing Compliance In Such Pt
    U-394 Method Of Use Of Alphagan
    U-395 Method Of Use Of Alphagan P
    U-396 Method Of Treating People Suffering From Depression
    U-397 Method Of Treating People Suffering From Depression Without An Increase In Nausea
    U-398 Treatment Of Generalized Anxiety Disorder
    U-399 In-The-Eye Use Of Chlorine Dioxide Containing Compositions
    U-4 Providing Prevention And Treatment Of Emesis And Nausea In Mammals
    U-40 Method Of Treatment Of Burns
    U-400 Use Of Ribavirin To Increase Type 1 Cytokine Response And Suppress Type 2 Cytokine Resp0nse To Lymphocytes, Including Methods That Take Advantage Of Such Modulation To Treat Infections And Infestations
    U-401 Use Of Lopinavir In Combination With Reverse Transcriptase Inhibitors For Treating Hiv Infection And In Combo With Other Hiv Protease Inhibitors
    U-402 Treatment Of Actinic Keratoses
    U-403 Anti-Allergic For Various Allergic Diseases
    U-404 Treatment Of Allergic Conjunctivitis
    U-405 For Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome (Ibs)
    U-406 Method Of Use Of Atovaquone And Proguanil
    U-407 Method Of Treating Otopathy
    U-408 For Inducing Ovulation In Conjunction With A Gonadotropin Releasing Factor Antagonist And Recruiting Oocytes For In-Vitro Fertilization
    U-409 Method Of Treating Inflammation Using Drug Substance
    U-41 Method Of Treating Cardiac Arrhythmias
    U-410 Method Of Reducing Amount Of Respective Active Components Administered To A Diabetic Patient By Administering A Chemical Compound Having A Particular Formula (Including Pioglitazone) In Combination With An Insulin Secretion Enhancer
    U-411 Method Of Reducing The Side Effects Of Active Components Administered To A Diabetic Patient By Administering A Chemical Compound Having A Particular Formula (Which Includes Pioglitazone) In Combination With An Insulin Preparation
    U-412 Treatment Of Type 2 Diabetes
    U-413 Use Of The Active Ingredient For Inhibiting The Biosynthesis Of Cholesterol And Treatment Of Atherosclerosis
    U-414 A Method Of Treating Glycometabolism Disorders By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide
    U-415 A Method For Reducing The Amount Of Active Components Administered To A Diabetic Patient By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide As Said Active Components
    U-416 A Method For Reducing Side Effects Of Active Components Administered To A Diabetic Patient By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide As Said Active Components
    U-417 Combination Use Of Ad-4833 With A Biguanide
    U-418 A Method Of Treating Lipid Metabolism Disorders By Administering A Chemical Compound Having A Particular Formula (Which Includes Pioglitazone) In Combination With An Insulin Secretion Enhancer
    U-419 A Method Of Treating Lipid Metabolism Disorders By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide
    U-42 Adjuvant Treatment In Combination With Fluorouracil After Surgical Resection In Patients With Dukes' Stage C Colon Cancer
    U-420 Method Of Treatment Of Type Ii Diabetes
    U-421 Use For Sedation
    U-422 Method Of Treating At Least One Of Attention Deficit Disorder And Attention Deficit Hyperactivity Disorder
    U-423 Method Of Treating At Least One Of Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Or Aids Related Dementia
    U-424 For Once Daily, Bolus Administration To A Patient In Order To Engender Treatment For A Nervous Disorder For Substantially An Entire Day On A Chronic Basis
    U-425 Method Of Reducing Side Effects Of Active Components Admin To A Diabetic By Admin A Chemical Compound Having Formula (Incl Pioglitazone) In Combination With An Insulin Secretion Enhancer
    U-426 Prevention Of Premature Lh Surges In Women Undergoing Controlled Ovarian Stimulation
    U-427 Method Of Treating Allergic Reactions In Mammals
    U-428 Method Of Treating Allergy In A Mammal Using This Active Metabolite
    U-429 Method Of Using Desloratadine To Treat Allergic Rhinitis
    U-43 Management Of Chronic Pain In Patients Requiring Opioid Analgesia
    U-430 Method Of Treating A Diabetic By Administering An Insulin Sensitizer In Combination With An Insulin Secretion Enhancer, And A Drug Product C0mprising An Insulin Sensitizer And An Insulin Secretion Enhancer
    U-431 Posttraumatic Stress Disorder
    U-432 Reduction Of Atherosclerotic Events (Myocardial Infarction, Stroke, And Vascular Death) In Patients With Atherosclerosis Documented By Recent Stroke, Recent Myocardial Infarction Or Established Peripheral Arterial Disease
    U-433 Use Of Levocaritine In Prevention And Treatment Of Carnitine Deficiency In Patients With End Stage Renal Disease Who Are Undergoing Dialysis
    U-434 Controlled Symptoms Of Diarrhea, Bloating Pressure And Cramps, Commonly Referred To As Gas
    U-435 A Titration Dosing Regimen For The Treatment Of Pain Using An Initial Dose Of About 25mg
    U-436 Acute Treatment Of Migraine Attacks With Or Without Aura In Adults
    U-437 Method Of Use Equal To Process Of Preparation
    U-438 Treatment/Prevention Of Neurodegenerative Disease
    U-439 Treatment Of Obesity
    U-44 Relief Of Nausea And Vomiting
    U-440 Method For Transdermal Administration Of A Drug Through Non-Scrotal Skin Using A Transdermal Drug Delivery Device Containing The Drug And Having An Adhesive Surface
    U-441 Method Of Treating Ms By Administering Copaxone
    U-442 Method For Delivering A Drug To A Patient In Need Of The Drug, While Avoiding The Occurence Of An Adverse Side Effect Known Or Suspected Of Being Caused By Said Drug
    U-443 Management Of Moderate To Severe Pain When A Continuous, Around-The-Clock Analgesic Is Needed For An Extended Period Of Time
    U-444 Treatment Of Migraine
    U-445 Use As An Antimycotic Agent
    U-446 Topical Treatment Of Ocular Hypertension And Glaucoma
    U-447 Method Of Treating Hyperlipidemia With Nicotinic Acid By Dosing Once Per Day In The Evening Or At Night
    U-448 Method Of Treating Hyperlipidemia With Nicotinic Acid Without Causing Treatment-Limiting Elevations In Uric Acid Or Glucose Levels Or Causing Liver Damage, By Dosing Once Per Day In The Evening Or At Night
    U-449 Use In Combination With 5-Fluorouracil And Leucovorin For The Treatment Of Metastatic Colorectal Cancer Where The Dose Of Leucovorin Is At Least 200mg Per Square Meter
    U-45 Treatment Of Inflammation And Analgesia
    U-450 Intermediate Rel Nicotinic Acid Formulations Having Unique Urinary Metab Profiles Resulting From Absorption Profiles Of Nicotinic Acid From The Intermediate Nicotinic Acid Formulations,Suitable For Tx Hyperlipidemia Following Qd Dosing
    U-451 Treatment Of Depression And Generalized Anxiety Disorder
    U-452 Use Of Lansoprazole For Combatting Diseases Caused By The Genus Campylobacter (C.Pylori=H.Pylori)
    U-453 Treatment Of Platelet Associated Ischemic Disorders
    U-454 Method Of Tx A Pt Suspected Of Having Hepatitis C By Admin, In Combination, A Conjugate Comprising Peg 12000 & Interferon Alfa-2b In An Amt Of From 0.5mcg/Kg To 2mcg/Kg, Once Weekly, And Ribavirin
    U-455 Treatment Of Pulmonary Hypertension With Ut-15
    U-456 Method Of Decreasing The Production Of A-Beta Using A Composition Which Decreases Blood Cholesterol In Patients At Risk Of Or Exhibiting Symptoms Of Alzheimer's Disease
    U-457 Method Of Treating A Vaginal Fungal Infection In A Female Human
    U-458 Method Of Use Of Imagent
    U-459 Treatment Of Depression And Generalized Anxiety Disorder
    U-46 Treatment Of Panic Disorder
    U-460 Method Of Treating Psychiatric Symptoms Associated With Premenstrual Disorders Using Sertraline
    U-461 Method Of Treatment Of Late Luteal Phase Dysphoric Disorder (Pmdd) Using Sertraline
    U-462 Signs And Symptoms Of Osteoarthritis And Adult Rheumatoid Arthritis And Treatment Of Primary Dysmenorrhea
    U-463 Venography
    U-464 Peripheral Arteriography
    U-465 Ct Imaging Of The Head
    U-466 Treatment Of Irritable Bowel Syndrome
    U-467 Use Of Eplerenone In Combination With An Angiotensin Converting Enzyme (Ace) Inhibitor For Treating Hypertension
    U-468 Method Of Using Fexofenadine Hcl In Treating Allergic Rhinitis
    U-469 Treatment Of Gastroesophageal Reflex Disease (Gerd) And Eradication Of H.Pylori To Reduce Risk Of Duodenal Ulcer Recurrence
    U-47 Stimulation Of The Release Of Growth Hormone
    U-470 Therapy In Chronic Hepatitis B Virus Infection
    U-471 Method Of Treating A Patient Suffering From Diabetes Mellitus
    U-472 Treatment Of Attention Deficit Hyperactivity Disorder Using Methylphenidate Bi-Modal Release Profile Extended-Release Capsules
    U-473 To Reduce Plasma Cholesterol Levels In A Mammal
    U-474 To Reduce Plasma Cholesterol Levels By Admin Ezetimibe In Combo With Cholesterol Biosynthesis Inhib Selected From Group Consisting Of Hmg Coa Reductase Inhibitors Incl Simvastatin
    U-475 Treatment Of Cutaneous Manifestations Of Cutaneous T-Cell Lymphoma In Patients Who Are Refractory To At Least One Prior Systemic Therapy
    U-476 Method Of Treating Androgen Responsive/Mediated Condition In Mammal By Admin A Safe, Effective Amount Of Dutasteride Or Pharmaceutically Acceptable Derivative Thereof..Conditions Include Benign Prostatic Hypertrophy
    U-477 Method Of Inhibiting 5 Alpha Testosterone Reductase Enzyme With Dutasteride Or Its Derivative And Treating Androgen Responsive/Mediated Disease Including Benign Prostatic Hyperplasia
    U-478 Method Of Treating Hepatitis C Viral Infection By Continuous Parenteral Admin Interferon Alpha 2-10 Million Iu Weekly, Subcutaneously, Injection Of Polymer-Interferon Alpha Conjugate-Polymer Is Peg-Interferon Is Alpha 2b
    U-479 Method Of Using Peg-Intron/Rebetol Combination Therapy And Intron/Rebetol Combination Therapy
    U-48 Analgesia
    U-480 Contrast Agent For Mri
    U-481 Disubstituted Acetylenes Bearing Heteroaromatic And Heterobicyclic Groups Having Retinoid-Like Activity
    U-482 Method Of In Vitro Fertilization Therapy Including Means For Inducing Ovulation....
    U-483 Method For The Administration Of Drugs Using That Compound
    U-484 Method Of Treating A Skin Disease With A Corticosteroid-Containing Pharmaceutical Composition
    U-485 Method And Composition For Reducing Nerve Injury Pain Associated With Shingles (Herpes Zoster And Post-Herpetic Neuralgia)
    U-486 External Preparation For Application To The Skin Containing Lidocaine-Drug Retaining Layer Placed On Support And Comprises Adhesive Gel Base 1-10% By Weight Of Lidocaine
    U-487 Method And Composition For Reducing Nerve Injury Pain Associated With Shingles (Herpes Zoster And Post-Herpetic Neuralgia)
    U-488 Method For Reducing The Pain Associated With Herpes-Zoster And Post-Herpetic Neuralgia
    U-489 Expectorant
    U-49 Symptomatic Cancer-Related Hypercalcemia
    U-490 Testosterone Replacement Therapy In Males For Conditions Associated With A Deficiency Or Absence Of Endogenous Testosterone
    U-491 Method Of Delivering A Drug To The Lung
    U-492 Method For The Treatment Of Skin, Suffering From A Condition Selected From A Group Consisting Of Nonacne Inflammatory Dermatoses... Comprising Applying To Affected Area. A Therapeutically Effective Amt Azelaic Acid
    U-493 Treatment Of Type 2 Diabetes Mellitus
    U-494 Treatment Of Attention-Deficit Hyperactivity Disorder
    U-495 Peritoneal Dialysis Solution
    U-496 Method For Treating Chronic Renal Failure
    U-497 Relief Of The Signs And Symptoms Of Osteoarthritis And Rheumatoid Arthritis
    U-498 Intra-Arterial And Intravenous Uses Of Ultravist
    U-499 Method Of Using Rebetol Capsules In Combination With A Conjugate Comprising Polyethylene Glycol(Peg) And An Alpha Interferon, Including, For Example, Peg-Intron Powder For Injection
    U-5 Method Of Producing Bronchodilation
    U-50 Use In Treating Inflammatory Dermatoses
    U-500 Use As An Antihypertensive Agent
    U-501 Treatment Of Recurrent Herpes Labialis (Cold Sores) In Adults
    U-502 Pityriasis Versicolor
    U-503 Generator Must Be Used With Infusion System Specifically Labeled For Use With Generator
    U-504 Tinea Pedis, Tinea Cruris, Tinea Corporis
    U-505 Ultrasound Contrast Agent
    U-506 Pharm Product Container 1st Chamber Is Disposed Aqueous Diluent Sol 2nd Chamber Pharm Active Agent Comprising Acetylcholine,Buffer In 1st Cham Is Sufficient To Buffer Ph Of Mixed Sol Resulting Mixture Of Aqueous Diluent Sol & Pharm Active..
    U-507 Acromegaly In Patients W/Inadequate Response To Surgery And/Or Radiation Therapy And/Or Medical Therapies, Or For Whom These Therapies Are Not Appropriate
    U-508 Method Of Releasing 17-Beta Oestradiol Precursor In A Substantially Zero Order Pattern For At Least Three Weeks
    U-509 Treatment Of Cutaneous Manifestations Of Cutaneous T-Cell Lymphoma In Patients Who Are Refractory To At Least One Prior Systemic Therapy
    U-51 Blood Pool Imaging, Including Cardiac First Pass And Gated Equilibrium Imaging And For Detection Of Sites Of Gastrointestinal Bleeding
    U-510 Topical Treatment Of Cutaneous Lesions In Patients With Cutaneous T-Cell Lymphoma (Stage Ia And Ib) Who Have Refractory Or Persistent Disease After Other Therapies Or Who Have Not Tolerated Other Therapies
    U-511 Use Of Quinolone Compounds Against Anaerobic Pathogenic Bacteria
    U-512 Use Of Quinolone Compounds Against Atypical Upper Respiratory Pathogenic Bacteria
    U-513 Methods Of Use Of Antimicrobial Compounds Against Pathogenic Amycoplasma Bacteria
    U-514 Prevention Of Ovulation In A Woman
    U-515 Treatment Of Multiple Myeloma Patients Who Have Received At Least Two Prior Therapies And Have Demonstrated Disease Progression On The Last Therapy
    U-516 Method Of Treating A Psychotic Disease
    U-517 Stable Gel Formulation For Topical Treatment Of Skin Conditions
    U-518 Obsessive Compulsive Disorder
    U-519 Post Operative Nausea And Vomiting
    U-52 Treatment Of Adult And Pediatric Patients(Over Six Months Of Age) With Advanced Hiv Infection
    U-520 Premenopausal Osteoporosis
    U-521 Method Of Using Ribavirin In Combination With Intron A (Interferon Alpha-2 B Recombinant) Injection To Treat Patients With Chronic Hepatitis C
    U-522 Treatment Of Cmv Retinitis By Intravitreal Admin Of A Phosphorothioate Oligonucleotide Capable Of Hybridizing With Cmv Mrna
    U-523 Method Of Treating Infection By Cryptosporidium Parvum In An Immunocompromised Mammal
    U-524 Method Of Treating Diarrhea
    U-525 Method Of Treating Parasitic Infections
    U-526 Method Of Providing Controlled Release Of A Treating Agent Using A Controlled Release Composition
    U-527 Method Of Delivering An Active Ingredient Using A Progressive Hydration Bioadhesive
    U-528 Prevention Of Chemotherapy-Induced Nausea And Vomiting
    U-529 Once Daily Treatment Of Asthma With Nebulized Budesonide
    U-53 Hypercalcemia Of Malignancy
    U-530 Treatment Of Herpes Zoster, Treatment Of Genital Herpes, Treatment Of Cold Sores, Suppression Of Genital Herpes In Immunocopetent And Hiv-Infected Individuals, Reduction Of Risk Of Heterosexual Transmission Of Genital Herpes
    U-531 Treatment Of Patients With Essential Hypertension. May Be Used Alone Or Given With Other Classes Of Antihypertensives, Especially Thiazide Derivatives
    U-532 Treatment Of Bronchospasm Associated With Copd In Patients Requiring More Than One Broncho Dilator
    U-533 Erectile Dysfunction
    U-534 Humalog Is An Insulin Analog That Is Indicated In The Treatment Of Patients With Diabetes Mellitus For The Control Of Hyperglycemia
    U-535 Treatment Of Social Anxiety Disorder
    U-536 Contrast Agent For Magnetic Resonace Imaging
    U-537 Treatment Of Conditions Related To Hyperaldosteronism Such As Hypertension And Cardiac Insufficiency, With Eplerenone
    U-538 First Line Treatment Of Severe Hypertension, In Patients With Hypertension Severe Enough That The Value Of Achieving Prompt Blood Pressure Control Exceeds The Risk Of Initiating Combination Therapy In These Patients
    U-539 Treatment Of Moderate To Severe Dementia Of The Alzheimer's Type
    U-54 Reversal Agent Or Antagonist Of Nondepolarizing Neuromuscular Blocking Agents
    U-540 Treatment Of Fungal Infections
    U-541 Method Of Treatment Of Adults Infected With Hiv-1
    U-542 Method Of Treating Patient With Type 2 Diabetes By Once Daily Administration
    U-543 Treatment Of Schizophrenia
    U-544 Treatment Of Overactive Bladder. Treatment Of Urinary Incontinence.
    U-545 Method For The Prevention And/Or Treatment Of Thrombotic Episodes, Such As Myocardial Infarction, In A Human Patient And Method For The Prevention Of Venous Thrombosis In A Postoperative Human Patient
    U-546 Use Of Repaglinide In Combination With Metformin To Lower Blood Glucose
    U-547 Maintenance Monotherapy For Bipolar Disorder
    U-548 A Method Of Reducing Flush In An Individual Being Treated For A Lipidemic Disorder And Effectively Treating The Lipidemic Disorder
    U-549 Use In The Treatment Of Men With Advanced Symptomatic Prostate Cancer
    U-55 Treatment Of Pain
    U-550 Treatment Of Bipolar Disorder And Schizophrenia
    U-551 Method For Reducing Toxicity Of Alimta Treated Patients By Administering Folic Acid
    U-552 Treatment Of Hypertension And Hyperlipidemia With A Single Composition
    U-553 Management Of Pain And Discomfort Associated With Peridontal Scaling And Root Planning Procedures By Application Of An Eutectic Mixture Of Local Anesthetics To Peridontal Pockets
    U-554 Treating Hiv Infection With Indinavir Sulfate In Combination With Antiretroviral Agents
    U-555 Treatment Of Complicated Urinary Tract Infections And Acute Uncomplicated Pyelonephritis
    U-556 Use As Adjunct Diagnostic For Serum Thyroglobulin (Tg) Testing
    U-557 Nasal Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms
    U-558 Indicated For The Relief Of Bronchospasm In Patients 2-12 Years Of Age With Asthma (Reversible Obstructive Airway Disease)
    U-559 Method Of Decreasing Or Reducing Parathyroid Hormone Level; Method Of Modulating Parathyroid Hormone Secretion;Method Of Treating Hyperparathyroidism; Method Of Reducing Serum Ionized Calcium Level
    U-56 Aid To Smoking Cessation
    U-560 Method Of Decreasing Parathyroid Hormone Level;Method Of Treating Hyperparathyroidism
    U-561 Cosopt Is Indicated For The Reduction Of Elevated Intraocular Pressure In Patients With Open-Angle Glaucoma Or Ocular Hypertension Who Are Insufficiently Responsive To Beta Blockers
    U-562 Topical Treatment Of Cutaneous Lesions In Patients With Aids-Related Kaposi's Sarcoma
    U-563 Marinol Is Indicated For, Inter Alia, Anorexia Associated With Weight Loss In Patients With Aids
    U-564 Treatment Of Hiv In Concomitant Therapy
    U-565 Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms, And Chronic Urticaria
    U-566 For The Long-Term, Once-Daily, Maintenance Treatment Of Bronchospasm Associated With Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And Emphysema
    U-567 Method Of Treating Infertility
    U-568 Method Of Using Fsh Alone (Without Exogenous Lh) In In Vitro Fertilization
    U-569 Method Of Using Fsh Alone (Without Exogenous Lh) In In Vitro Fertilization And Wherein Thereafter An Ovulatory Inducing Amount Of Hcg Is Administered
    U-57 Ophthalmic Use Of Norfloxacin
    U-570 Method Of Using Fsh Alone (Without Exogenous Lh) In In Vitro Fertilization And Wherein The Daily Amount Of Fsh Is About 5-10 Iu/Kg
    U-571 Treatment Of Agitation Associated With Schizophrenia And Bipolar I Mania
    U-572 Intensive Care Unit Sedation
    U-573 Treatment Of Acute Promyelogenous Leukemia (Apl)
    U-574 Prophylaxis And Treatment Of The Nasal Symptoms Of Seasonal Allergic Rhinitis And Treatment Of The Nasal Symptoms Of Perennial Allergic Rhinitis In Adults And Pediatric Patients 12 Years Of Age And Older
    U-575 Lotemax Opthalmic Suspension Is Indicated For The Treatment Of Steroid Responsive Conditions Of The Palpebral Bulbar Conjunctiva, Cornea And Anterior Segment Of The Globe.
    U-576 Alrex Opthalmic Suspension Is Indicated For The Temporary Relief Of The Signs And Symptoms Of Seasonal Allergic Conjunctivitis.
    U-577 Treatment Of Benign Prostatic Hyperplasia With Finasteride In Combination With Doxazosin
    U-578 Treatment Of Community Acquired Pneumonia, Acute Exacerbation Of Chronic Bronchitis, And Acute Bacterial Sinusitis Caused By Susceptible Strains Of Designated Microorganisms In Patients 18 Years And Older.
    U-579 Treatment Of Epilepsy And/Or Migraine.
    U-58 Method Of Treating Inflammatory Intestinal Diseases
    U-580 Treatment Of Disorders Of The Serotonergic System Such As Depression And Anxiety-Related Disorders
    U-581 Method Of Treating A Condition Capable Of Treatment By Inhalation, E.G. Asthma, Comprising Administration Of A Formulation Claimed In Us Patent No. 6743413
    U-582 Method For The Treatment Of A Respiratory Disorder, E.G. Asthma, Comprising Administering An Effective Amount Of An Aerosol Composition To A Patient From A Metered Dose Inhaler System As Claimed In Us Patent No. 6253762
    U-583 Method For The Treatment Of A Respiratory Disorder, E.G. Asthma, Comprising Administering To A Patient By Inhalation, A Metered Aerosol Dose Of A Drug Formulation From The Metered Dose Inhaler System Claimed In Us 6546928
    U-584 Single-Dose Administration By The Epidural Route, At The Lumbar Level, For The Treatment Of Pain Following Major Surgery
    U-585 To Promote Weight Gain After Weight Loss In Certain Types Of Patients
    U-586 An Intermediate Release Nicotinic Acid Formulation Suitable For Oral Administration Once-A-Day As A Single Dose For Treating Hyperlipidemia Without Causing Drug-Induced Hepatotoxicity Or Elevations In Uric Acid Or Glucose Or Both
    U-587 Use Of Eplerenone In Combination With An Angiotensin Converting Enzyme (Ace) Inhibitor (And Optionally A Diuretic) For Treating Congestive Heart Failure And Hypertension
    U-588 Short-Term Treatment Of Active Duodenal Ulcer; Treatment Of Heartburn And Other Symptoms Associated With Gerd; Short-Term Treatment Of Erosive Esophagitis; Maintenance Of Healing Of Erosive Esophagitis
    U-589 Method For Treatment Of A Respiratory Disorder, E.G., Bronchospasm, Comprising Administering An Effective Amount Of An Aerosol Composition To A Patient From A Metered Dose Inhaler System As Claimed In U.S. Patent No. 6131966
    U-59 Method Of Treating Hypercholesterolemia
    U-590 Method For Treatment Of A Respiratory Disorder,E.G.,Bronchospasm,Comprising Administering To A Patient By Oral Or Nasal Inhalation A Drug Formulation By Using The Metered Dose Inhaler System As Claimed In Us Patent No.6532955
    U-591 Treatment Of Attention Deficit Hyperactivity Disorder Using A Dosage Form Which Provides Once-Daily Oral Administration Of A Phenidate Drug
    U-592 Treatment Of Primary Hypercholesterolemia, Mixed Hyperlipidemia And/Or Homozygous Familial Hypercholesterolemia (Hofh)
    U-593 Treatment Of Primary Hypercholesterolemia, Mixed Hyperlipidemia And/Or Homozygous Familial Hypercholesterolemia (Hofh)
    U-594 Prevention Of Postmenopausal Osteoporosis
    U-595 35 Mg Orally Once A Week For Prevention Of Osteoporosis In Postmenopausal Women; 35 Mg Orally Once A Week For Treatment Of Osteoporosis In Postmenopausal Women
    U-596 Treatment Of Hormone Receptor Positive Metastatic Breast Cancer In Postmenopausal Women With Disease Progression Following Antiestrogen Therapy
    U-597 Forteo Is Indicated For The Treatment Of Post Menopausal Women With Osteoporosis Who Are At High Risk For Fracture
    U-598 Prophylactic Treatment Of Migraine
    U-599 Method For Treating Allergic Conjunctivitis
    U-6 Method Of Producing Sympathomimetic Effects
    U-60 Nasal Administration Of Butorphanol
    U-600 A Method Of Treating A Patient In Need Of Ophthalmic Antimicrobial Therapy With Levofloxacin
    U-601 Treatment Of Bipolar Disorder
    U-602 Signs And Symptoms Of Osteoarthritis, Rheumatoid Arthritis In Adults, And/Or Pauciarticular Or Polyarticular Course Juvenile Rheumatoid Arthritis, Acute Pain In Adults; Primary Dysmenorrhea; And/Or Acute Migraine Attacks In Adults
    U-603 Method Of Treating Infections Comprising Orally Administering An Effective Amount Of The Fda Approved Oral Suspension
    U-604 Method Of Lowering Blood Glucose By Once Daily Administration
    U-605 Treatment Of Major Depressive Disorder(Mdd);Although The Mehchanism Of The Antidepressant Action Of Duloxetine In Humans Is Unknown, It Is Believed To Be Related To Its Potentiation Of Seratonergic And Noradrenergic Activity In The Cns
    U-606 Use Of Irinotecan In Combination With 5-Fluorouracil And Leucovorin For The Treatment Of Metastatic Colrectal Cancer
    U-607 Cancidas Is Indicated For Empirical Therapy For Presumed Fungal Infections In Febrile, Neutropenic Patients.
    U-608 Use Of Quinolone Compounds Against Pneumococcal Pathogenic Bacteria
    U-609 Use Of Quinolone Compounds Against Quinolone-Resistant Pneumococcal Pathogenic Bacteria
    U-61 Cerebral And Peripheral Arteriography And Ct Imaging Of The Head
    U-610 Atrovent Hfa (Ipratropium Bromide Hfa) Inhalation Aerosol Is Indicated As A Bronchodilator For Maintenance Treatment Of Bronchospasm Associated With Chronic Obstructive Pulmonary Disease, Including Chronic Bronchitis And Emphysema.
    U-611 Method Of Using Desloratadine To Treat Seasonal And Perennial Allergic Rhinitis, Pruritis, And Chronic Idiopathic Urticaria In Patients 2 Years Of Age And Older
    U-612 Treatment Of Seasonal Allergy Symptoms With Nasal Congestion In Adults And Children 12 Years Of Age And Older
    U-613 Reduction Of Serum Phosphate
    U-614 Treatment Of Sexual Dysfunction
    U-615 Adjunctive Therapy To Diet In Adults To Reduce Ldl-C, Total-C, Triglycerides And Apo B, And Increase Hdl-C In Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (Types Iia, Iib) And To Treat Hypertriglyceridemia (Types Iv, V)
    U-616 Management Of Persistent, Moderate To Severe Pain In Patients Requiring Continuous, Around-The-Clock Analgesia With A High Potency Opioid For An Extended Period Of Time Generally Weeks To Months Or Longer
    U-617 Treatment Of Acute Promyelogenous Leukemia (Apl)
    U-618 Use Of Rosuvastatin Calcium To Reduce Elevated Total-C, Ldl-C, Apob, Nonhdl-C Or Tg Levels; To Increase Hdl-C In Adult Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia; And To Slow The Progression Of Atherosclerosis.
    U-619 Treatment Of Malignant Neoplasm
    U-62 Coronary Arteriography, Left Ventriculography, Ct Imaging Of The Body, Intravenous Excretory Urography, Intravenous Digital Subtraction Angiography And Venography
    U-620 Treatment Of Insomnia
    U-621 Method Of Treating Cancer
    U-622 Treatment Of Vegf Mediated Ocular Disease.
    U-623 Short Term Treatment Of Active Benign Gastric Ulcer
    U-624 Reduction Of Risk Of Upper Gastrointestinal Bleeding In Critically Ill Patients
    U-625 Allergic Rhinitis Or Nasal Polyps
    U-626 Clolar Is Indicated For The Treatment Of Pediatric Patients 1 To 21 Years Old With Relapsed Or Refractory Acute Lymphoblastic Leukemia After At Least Two Prior Regimens
    U-627 Treatment Of Patients Using Extended-Release Carbamazepine
    U-628 Use Of Avandia In Combination With A Sulfonylurea, And In Combination With Metformin And A Sulfonylurea To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus
    U-629 Method Of Inducing A Hypnotic Or Sedative Effect In A Human By Administering Eszopiclone
    U-63 Isoprenaline Antagonism On The Heart Rate Or Blood Pressure
    U-630 Treating Urinary Incontinence By Administering An Extended-Release Form Of Darifenacin
    U-631 Treating A Disease Of Altered Motility Or Tone Of Smooth Muscle By Administering A Muscarinic Receptor Antagonizing Amount Of Darifenacin
    U-632 Method Of Treatment Of Cancer By Administering Particles Of Paclitaxel That Have A Protein Coating
    U-633 Method For Treatment Of Tumors By Administering Paclitaxel At A Dose In The Range Of About 30mg/Meter Square To About 100mg/Meter Square In A Pharmaceutically Acceptable Formulation That Does Not Contain Cremophor
    U-634 Method For Delivery Of A Biologic (Including Antineoplastic Agents) By Administering To A Patient An Effective Amount Of A Biologic As A Solid Or Liquid With A Polymeric Biocompatible Material
    U-635 Treatment Of Gerd, Maintenance Of Healing Of Erosive Esophagitis And Risk Reduction Of Nsaid Associated Gastric Ulcers
    U-636 Treatment Or Prevention Of Bronchospasm Or Asthmatic Symptoms
    U-637 Treatment Of Diabetes With An Amylin Agonist
    U-638 Treatment Of Diabetes With An Amylin Agonist, Including With Insulin
    U-639 Treatment Of A Mammal Having A Need Of Or Reduced Ability To Produce Insulin With An Insulin And An Amylin Such As Pramlintide
    U-64 Treatment Of Viral Infections
    U-640 Use Of An Amylin Agonist To Reduce Gastric Motility And Treat Post Prandial Hypergylcemia
    U-641 Use Of An Amylin Agonist Having Specified Binding Activity To Reduce Gastric Motility, Including Use Through Parenteral Administration
    U-642 Treatment And Prevention Of Osteoporosis
    U-643 The Short Term Treatment (Up To 10 Days) In Pts Having Gastroesophageal Reflux Disease (Gerd) As An Alternative To Oral Therapy In Pts When Therapy With Nexium Capsules Is Not Possible Or Appropriate
    U-644 Treatment Of Seasonal Allergic Rhinitis
    U-645 Treatment Of Asthma
    U-646 Method Of Treating Otitis
    U-647 Treatment Of Osteoporosis In Post Menopausal Women And/Or The Treatment To Increase Bone Mass In Men With Osteoporosis
    U-648 The Treatment Of Osteoporosis In Postmenopausal Women And/Or The Treatment To Increase Bone Mass In Men
    U-649 A Method For Treating A Tumor Disease
    U-65 Method Of Treatment Of A Patient Infected With Hiv
    U-650 Treatment Of Esophageal Candidiasis And Prophylaxis Of Candida Infections In Hsct Patients
    U-651 Treatment Of Acute Promyelocytic Leukemia (Apl)
    U-652 Treatment Of Cardiac Arrhythmia
    U-653 Stimulating Insulin Release By Administering Exenatide
    U-654 Lowering Plasma Glucagon In A Subject In Need Thereof, Including One With Type 2 Diabetes, By Administering An Exedin Or Analog, Such As Exendin-4
    U-655 Treatment Of Mild To Moderate Active Chrohn's Disease Involving The Ileum And/Or The Ascending Colon And The Maintenance Of Clinical Remission Of Mild To Moderate Crohn's Disease Involving The Ileum And/Or Ascending Colon For Up To 3 Months
    U-656 Reducing Gastric Motility Or Delaying Gastric Emptying By Administering An Exendin, Such As Exendin-4
    U-657 Prevention Of Osteoporosis In Postmenopausal Women
    U-658 Treatment Of Advanced Hormone-Dependent Breast Cancer
    U-659 Treatment Of Locally Advanced Or Metastatic Non Small-Cell Lung Cancer (Nsclc) After Failure Of At Least One Prior Chemotherapy Regimen
    U-66 Triphasic Regimen
    U-660 Treatment Of Hypertension And Treatment Of Heart Failure
    U-661 Treatment Of Seizure Disorder
    U-662 Treatment Of Osteoporosis In Postmenopausal Women
    U-663 The Treatment Of Uncomplicated Urinary Tract Infections
    U-664 Treatment Of Conditions For Which An Aldosterone Receptor Blocker Is Indicated, Such As Hypertension, Heart Failure, And Post-Myocardial Infarction
    U-665 Method Of Using The Drug Substance/Drug Product For Ultrasound Imaging
    U-666 Method Of Treating Adhd
    U-667 Management Of Incontinence; Method For Treating Incontinence
    U-668 Levemir Is A Long-Acting Basal Insulin Analog That Is Indicated In The Treatment Of Patients With Diabetes Mellitus
    U-669 Indication Of Type Ii Diabetes
    U-67 Method Of Inducing Anesthesia In A Warm Blooded Animal
    U-670 Treatment Of Hiv-1 Infection By The Co-Administration Of Tipranavir And Ritonavir.
    U-671 Prevention And Treatment Of Secondary Hyperparathyroidism Associated With Chronic Kidney Disease (Ckd) Stage 3 And 4
    U-672 Treatment Of Inflammation Or An Inflammation-Associated Disorder
    U-673 Method Of Treatment With Once-Daily Doses Of 625mg/5ml
    U-674 Method Of Treating Insomnia Charachterized By Difficulty With Sleep Onset
    U-675 Prophylaxis And Chronic Treatment Of Asthma; Relief Of Symptoms Of Allergic Rhinitis
    U-676 Method Of Treating Attention Deficit Disorder Using Oral Administration Of A Bi-Modal Or Pulsatile Release Composition
    U-677 A Method Of Treating Disease Amenable To Treatment With A Phenidate Drug By Once Daily Oral Administration Of An Extended Release Dosage Form
    U-678 Method Of Treating Attention Deficit Disorder And/Or Attention Deficit Hyperactivity Disorder
    U-679 Adjunct To Diet And Exercise To Improve Glycemic Control In Patients With Type 2 Diabetes Who Are Already Treated With A Pioglitazone And Metformin
    U-68 Treatment Of Actinic Keratosis
    U-680 A Method Of Treating Dyslipidemia And Dyslipoproteinemia Using A Dosage Form That Can Provide An Effective Amount Of Fenofibrate To A Patient In A Fasted State Which Is At Least 90% Of The Auc Amount Provided By The Dosage Form
    U-681 Treatment Of Primary Igf-1 Deficiency
    U-682 Non-Benzodiazepine Hypnotic Agent Indicated For Treatment Of Insomnia, Characterized By Difficulties With Sleep Onset And/Or Sleep Maintenance
    U-683 Prevention Or Treatment Of Ischemic Heart Disease
    U-684 Treatment Of Uncomplicated Skin Manifestations Of Chronic Idiopathic Urticaria In Adults And Children 6 Years Of Age And Older
    U-685 Expectorant And Cough Suppressant
    U-686 Expectorant And Nasal Decongestant
    U-687 Reducing Food Intake In A Subject With Type 2 Diabetes By Administering An Exendin, Such As Exendin-4
    U-688 Treatment Of Hiv-Infection In Combination With Other Antiretroviral Agents
    U-689 Treatment Of Patients With T-Cell Acute Lymphoblastic Leukemia Whose Disease Has Not Responded To Or Has Relapsed Following Treatment With At Least Two Chemotherapy Regimens
    U-69 Treatment Of Pneumocystis Carinii Infections
    U-690 To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus
    U-691 Use As A Monotherapy, In Combination With A Sulfonylurea, Metformin Or Insulin Or In Combination With A Sulfonylurea Plus Metformin To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus
    U-692 Use Of Valsartan To Reduce Cardiovascular Mortality In Clinically Stable Patients With Left Ventricular Failure Or Left Ventricular Dysfunction Following Myocardial Infarction
    U-693 The Recommended Initial Dose Of Equetro Is 400mg/Day Given In Divided Doses, Twice Daily. The Dose Should Be Adjusted In 200mg Daily Increments To Achieve Optimal Clinical Response.
    U-694 Lenalidomide Is An Analogue Of Thalidomide. Thalidomide Is A Known Human Teratogen That Causes Severe Life-Threatening Human Birth Defects. If Lenalidomide Is Taken During Pregnancy, It May Cause Birth Defects Or Death To An Unborn Baby.
    U-695 Treatment Of Patients With T-Cell Acute Lymphoblastic Leukemia And T-Cell Lymphoblastic Lymphoma Whose Disease Has Not Responded To Or Has Relapsed Following Treatment With At Least Two Chemotherapy Regimens
    U-696 Treatment Of Patients With T-Cell Lymphoblastic Lymphoma Whose Disease Has Not Responded To Or Has Relapsed Following Treatment With At Least Two Chemotherapy Regimens
    U-697 A Method Of Using Rinfabate Recombinant (Rhigfbp-3) With Mecasermin Recombinant (Rhigf-1) To Promote Linear Growth In The Tratment Of Primary Igf-1 Deficiency
    U-698 Method Of Using Antagonist Of Arginine Vasopressin (Ava) V1a And V2 Receptors For Intravenous Treatment Of Pateints With Euvolemic Hyponatremia
    U-699 Nasal Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms
    U-7 Increasing Cardiac Contractility
    U-70 Treatment Of Transient Insomnia
    U-700 Treatment And Prevention Of Osteoporosis In Postmenopausal Women
    U-701 Treatment Of Hypercholesterolemia And/Or Hypertriglyceridemia
    U-702 Topical Aerosol Hair Regrowth Treatment
    U-703 Treatment Of Protein Kinase Related Disorders, Such As Gastrointestinal Stromal Tumor And Renal Cell Carcinoma With Sunitinib
    U-704 Method Of Administering Insulin Via Inhalation
    U-705 Treating Chronic Angina By Administering An Extended Release Form Of Ranolazine
    U-706 Treatment Of Benign Prostatic Hyperplasia
    U-707 Allergic Rhinitis
    U-708 Treatment Of Chronic Non-Infectious Uveitis Affecting The Posterior Segment Of The Eye
    U-709 Method Of Combating Bacteria In A Patient
    U-71 Method Of Treatment Of Heart Failure
    U-710 A Method Of Treating Respiratory Disorders, E.G., Asthma, Which Comprises Administration By Inhalation Of An Effective Amount Of A Pharmaceutical Formulation As Claimed In Us Patent No. 5658549
    U-711 Acute And Longer-Term Treatment Of Major Depressive Disorder
    U-712 A Method Of Using A Nicotinic Acid Formulation To Reduce Elevated Tc, Ldl-C And Tg Levels, And Raise Hdl-C Levels In Patients With Hyperlipidemia
    U-713 Treatment Of Mild To Moderate Dementia Of The Alzheimer's Type
    U-714 Topical Treatment Of Interdigital Tinea Pedis And Tinea Corporis Due To Trichophyton Rubrum, Trichophyton Mentagrophytes Or Epidermophyton Floccosum
    U-715 For Cleansing The Bowel In Preparation For Colonoscopy, In Adults 18 Years Of Age Or Older
    U-716 The Treatment Or Prevention Of Bronchospasm In Adults And Children 4 Years Of Age And Older With Reversible Obstructive Airways Disease And The Prevention Of Exercised-Induced Bronchospasm In Patients 4 Years Of Age And Older
    U-717 Method Of Relieving Or Preventing Constipation In A Human Constipated Patient
    U-718 Treatment Of Fungal Infections
    U-719 Treatent Of Psychosis
    U-72 Treatment Of Migraine
    U-720 Treatment Of Neuroleptic Diseases
    U-721 Treatment Of Influenza
    U-722 Prophylaxis Of Influenza
    U-723 Prophylactic Treatment Of Migraine
    U-724 Method Of Treating Seizures
    U-725 Allergic Rhinitis And Urticaria
    U-726 Allergic Rhinitis
    U-727 For The Treatment Of Attention Deficit Hyperactivity Disorder (Adhd)
    U-728 Method For Treating Bacterial Infection
    U-729 Treatment Of Gastroesophageal Reflux Disease (Gerd), Risk-Reduction Of Nsaid-Associated Gastric Ulcer, H. Pylori Eradication To Reduce The Risk Of Duodenal Ulcer Recurrence
    U-73 Method Of Treating Diseases Or Infections Caused By Mycetes
    U-730 Use As A Nasal Spray For Treatment Of The Symptoms Of Seasonal Allergic Rhinitis And Vasomotor Rhinitis
    U-731 Use In Combination With Dexamethasone Is Indicated For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma
    U-732 Acute Treatment Of The Cutaneous Manifestations Of Moderate To Severe Erythema Nodosum Leprosum (Enl)
    U-733 Maintenance Therapy For Prevention And Supression Of The Cutaneous Manifestations Of Enl Recurrence
    U-734 First Line Therapy For Type 2 Diabetes Mellitus
    U-735 Method Of Treating Chronic Iron Overload
    U-736 Method For Iontophoretic Transdermal Delivery Of Fentanyl Hydrochloride
    U-737 Disinfection Of Patient Skin Prior To An Invasive Procedure
    U-738 Indicated For The Long-Term, Twice-Daily Maintenance Treatment Of Asthma In Patients 12 Years Of Age Or Older
    U-739 Method For Treating Constipation By Opening Cic Channels In A Mamalian Subject
    U-74 Method Of Providing Hypnotic Effect
    U-740 For The Treatment Of Patients With Primary Biliary Cirrhosis
    U-741 Combination Therapy With Cisplatin For The Treatment Of Late Stage Cervical Cancer
    U-742 Twice Daily Topical Treatment Of Moderate To Severe Plaque Psoriasis.
    U-743 Once A Day Topical Treatment Of The Inflammatory Lesions Of Rosacea
    U-744 Treatment Of Hiv Infection In Antiretroviral Treatment-Experienced Adult Patients
    U-745 Treatment Or Prevention Of Emesis
    U-746 Prevention Or Treatment Of Nausea Or Emesis Induced By A Cancer Chemotherapeutic Agent
    U-747 Prevention Or Treatment Of Post-Operative Nausea And Vomiting
    U-748 A Method For The Treatment Of A Protein Tyrosine Kinase-Associated Disorder
    U-749 Method Of Contraception
    U-75 Relief Of Ocular Itching Due To Seasonal Allergic Conjunctivitis
    U-750 Treatment Of Hiv-1 Infection In Adults
    U-751 Once Daily Dosing Of Budesonide Via Nebulizer For The Treatment Of Asthma
    U-752 Sunscreen
    U-753 As An Adjunct To Diet And Exercise To Improve Glycemic Control In Patients With Type 2 Diabetes
    U-754 Use For The Long-Term Maintenance Treatment Of Asthma
    U-755 Treatment Of Anorexia, Cachexia, Or An Unexplained, Significant Weight Loss In Patients With A Diagnosis Of Acquired Immunodeficiency Syndrome (Aids)
    U-756 Addition Of Once-Weekly Dosing For The Treatment To Increase Bone Mass In Men With Osteoporosis
    U-757 Use As A Bile Acid Sequestrant For Lowering Cholesterol
    U-758 Treatment Of Symptoms Of Premenstrual Dysphoric Disorder
    U-759 Method Of Use Of Administering Levothyroxine
    U-76 Use To Image A Subject With A Magnetic Resonance Imaging System
    U-760 Prophylaxis Of Invasive Aspergillus And Candida Infections And Treatment Of Oropharyngeal Candidaiasis
    U-761 Treatment Of Schizophrenia Including Maintaining Stability In Patients With Schizophrenia
    U-762 Treatment Of Chronic Obstructive Pulmonary Disease
    U-763 Administration Of Aripiprazole By Injection
    U-764 Treatment Of Schizophrenia
    U-765 Method Of Treating Allergic Conjunctivitis
    U-766 Treatment Of Seizures
    U-767 Management Of Breakthrough Pain In Patients With Cancer
    U-768 A Method Of Reducing The Capacity Of Extended Release Nicotinic Acid To Provoke A Flushing Reaction By Pretreating An Individual With A Flush Inhibiting Agent Prior To The Administration Of The Extended Release Nicotinic Acid
    U-769 Revlimid (Lenalidomide) In Combination With Dexamethasone Is Indicated For The Treatment Of Multiple Myeloma Patients Who Have Received At Leaset One Prior Therapy
    U-77 Treatment Of Symptoms Of Seasonal Allergic Rhinitis
    U-770 Long-Term Treatment Of Pathological Hypersecretory Conditions
    U-771 Method For The Treatment Of Diabetes Mellitus, Such As Type 1 Diabetes Mellitus Or Type 2 Diabetes Melitus, In A Human Patient
    U-772 Relief Of Symptoms Associated With Seasonal Allergic Rhinitis In Children 2 To 11 Years And For The Relief Of Symptoms Associated With Uncomplicated Skin Manifestations Of Chronic Idiopathic Urticaria In Children 6 Months To 11 Years
    U-773 Pathological Hypersecretory Conditions
    U-774 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidaste-Iv Inhibitor
    U-775 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-Iv Inhibitor In Combination With Metformin And/Or A Sulfonylurea
    U-776 Treatment Of Cutaneous Manifestation In Patients With Cutaneous T-Cell Lymphoma (Ctcl) Who Have Progressive, Persistent Or Recurrent Disease On Or Following Two Systemic Therapies.
    U-777 Decreasing Mortality Caused By Congestive Heart Failure
    U-778 Reduction Of Elevated Intraocular Pressure In Pateints With Open Angle Glaucoma Or Ocular Hypertension
    U-779 A Method For Treatment Of A Cancer, Wherein The Cancer Is Chronic Myelogenous Leukemia
    U-78 Ulcerative Colitis
    U-780 A Method For The Treatment Of Cancer
    U-781 For Treatment Of Adult Patients With Type 2 Diabetes Mellitus Who Are Naive To Pharmacologic Therapy
    U-782 Treatment Of Chronic Hepatitis B In Adult Patients With Evidence Of Viral Replication And Either Evidence Of Persistant Elevations In Serum Aminotransferases (Alt Or Ast) Or Histologically Active Disease
    U-783 Desonate Gel Is Indicated For The Treatment Of Mild To Moderate Atopic Dermatitis In Patients 3 Months Of Age And Older
    U-784 Treatment Of Moderate To Severe Primary Restless Legs Syndrome (Rls)
    U-785 Use As Replacement Solution, Hemofiltration Solution Or Hemodiafiltration Solution In Continuous Renal Replacement Therapy
    U-786 Product Is Approved For The Topical Treatment Of Tinea Pedis
    U-787 Maintenance Treatment Of Asthma As Prophylactic Therapy In Adult And Pediatric Patients Six Years Of Age Or Older, Including Patients Requiring Oral Corticosteroid Therapy For Asthma
    U-788 Method Of Treating Psychiatric Symptoms Associated With Premenstrual Disorders Using Paroxetine
    U-789 Treatment Of Known Or Suspected Cyanide Poisoning
    U-79 Symptomatic Treatment Of Patients With Nocturnal Heartburndue To Gerd
    U-790 Forteo Is Indicated For The Treatment Of Post Menopausal Women With Osteoporosis Who Are At Risk For Fracture. Forteo Can Be Used By People Who Have Had A Fracture Related To Osteoporosis
    U-791 Gleevec Is Also Indicated For The Treatment Of Patients With Kit (Cd117) Positive Unresectable And/Or Metastatic Malignant Gastrointestinal Stromal Tumors (Gist)
    U-792 Treatment Of Seborrhea Dermatitis In Humans
    U-793 For The Long Term Treatment, Twice Daily (Morning And Evening) Maintenance Treatment Of Bronchoconstriction In Patients With Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And Emphysema
    U-794 Closure Of A Clnically Significant Patent Ductus Arteriosus In Premature Infants Weighing Between 500 And 1500g, Who Are No More Than 32 Weeks Gestational Age When Usual Medical Management Is Ineffective
    U-795 Method For Inhibiting Norepinephrine Uptake
    U-796 Method Of Treating Depression
    U-797 Method Of Treating Anxiety
    U-798 Treatment And Prevention Of Osteoporosis In Postmenopausal Women By Once-Monthly Oral Administration Of Ibandronate Sodium Monohydrate Equivalent To 150mg Of Ibandronic Acid
    U-799 Method For Inhibiting Serotonin Uptake
    U-8 Acute Myocardial Infarction
    U-80 Method Of Treating Ocular Bacterial Infections
    U-800 Treatment Of Patients With Advanced Or Metastatic Breast Cancer Whose Tumors Overexpress Her2 And Who Have Received Prior Therapy Including Anthracycline, A Taxane And Trastuzumab
    U-801 Method Of Treating Cancer
    U-802 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-Iv Inhibitor
    U-803 Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-Iv Inhibitor In Combination With Metformin
    U-804 Treatment Of Actinic Keratoses By Photodynamic Therapy
    U-805 Treatment Of Impetigo Due To Staphylococcus Aureus Or Streptococcus Pyogenes
    U-806 Intrathecal Treatment Of Lymphomatous Meningitis
    U-807 Prevention Of Exercise-Induced Bronchoconstriction
    U-808 The Treatment Of The Symptoms Of Seasonal And Perennial Allergic Rhinitis In Patients 2 Years Of Age And Older
    U-809 Treatment Of Chronic Idiopathic Urticaria
    U-81 Relief Of Symptoms Associated With Seasonal Allergic Rhinitis
    U-810 Method Of Treatment To Alleviate Inflammation Of The Eye
    U-811 Relief Of Symptoms Associated With Seasonal And Perennial Allergic Rhinitis And Treatment Of The Uncomplicated Skin Manifestations Of Chronic Idiopathic Urticaria
    U-812 Relief Of Symptoms Associated With Seasonal And Perennial Allergic Rhinitis
    U-813 Maintenance Treatment Of Bronchoconstriction In Patients With Chronic Obstructive Pulmonary Disease (Copd)
    U-814 Treatment Of Schizophrenia
    U-815 Treats Cold Sores/Fever Blisters On The Face Or Lips. Shortens Healing Time And Duration Of Symptoms: Tingling, Pain, Burning And/Or Itching
    U-816 Depression, Panic Disorder, Premenstrual Disorders And Social Anxiety Disorder
    U-817 Nasal Administration Of Cyanocobalamin
    U-818 Topical Treatment Of Acne Vulgaris
    U-819 Management Of Fibromyalgia
    U-82 Treatment For Dementia In Patients With Alzheimer's Disease
    U-820 Improved Wakefulness In Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, And Shift Work Sleep Disorder
    U-821 Method Of Inhibiting Enthothelin Receptors By Administering Ambrisentan To A Patient To Treat Pulmonary Arterial Hypertension.
    U-822 Use In Lipid Management
    U-823 Relief Of Symptoms Associated With Seasonal Allergic Rhinitis And For The Treatment Of Uncomplcated Skin Manifestations Of Chronic Idiopathic Urticaria In Children 6 To 11 Years Of Age
    U-824 Method Of Treating Patients Infected With Ccr5-Tropic Hiv-1
    U-825 Use For Prevention Of Breast Cancer
    U-826 Relief Of Moderate To Severe Pain
    U-827 Use For Treatment Of Diabetes, Particularly Type 2 Diabetes
    U-828 Prevention Of Pregnancy In Women Who Elect To Use Oral Contraceptives As A Method Of Contraception
    U-829 Treatment Of Extravasation Resulting From Iv Anthracycline Chemotherapy
    U-83 Treatment Of Seizures
    U-830 Treatment Of Relapsed Small Cell Lung Cancer
    U-831 Method Of Administering Lanreotide Acetate
    U-832 Zingo Is Indicated For The Use On Intact Skin To Provide Local Analgesia Prior To Venipuncture Or Intravenous Cannulation.
    U-833 Method Of Treating Pain Using A Pharmaceutically Acceptable Salt Of Ropivacaine And Administering A Composition Containing Less Than 0.25% By Weight Of Ropivacaine
    U-834 Invirase In Combination With Ritonavir And Other Antiretroviral Agents Is Indicated For The Treatment Of Hiv Infection
    U-835 Relief Of The Inflammatory And Pruritic Manifestations Of Atopic Dermatitis In Patients One Year Of Age Or Older
    U-836 A Method For The Treatment Of Leukemias
    U-837 Gastrointestinal Lavage Indicated For Cleansing Of The Colon As A Preparation For Colonoscopy In Adults
    U-838 Method Of Treating Pain Using A Pharmaceutically Acceptable Salt Of Ropivacaine And Administering A Composition Containing Less Than 0.5% By Weight Of Ropivacaine
    U-839 Treatment Of Major Depressive Disorder (Mdd)
    U-84 A Method Of Blocking The Uptake Of Monoamines By Brain Neurons In Animals
    U-840 Treatment For Type 2 Diabetes Mellitus
    U-841 Indicated For The Long-Term, Maintenance Treatment Of Asthma In Patients 12 Years Of Age And Older
    U-842 Indicated For The Treatment Of Attention-Deficit/Hyperactivity Disorder (Adhd)
    U-843 Method For Administration Of Testosterone
    U-844 Prefest Is Indicated In Women Who Have A Uterus For The Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause; Treatment Of Vulvar And Vaginal Atrophy; Prevention Of Osteoporosis
    U-845 Treatment Of Patients With Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis And Abcesses
    U-846 Use For Delineation (Visualization) During A Vitrectomy Surgical Procedure
    U-847 Adjunctive Therapy To Diet In Adults To Reduce Ldl-C, Triglycerides And Apo B, And Increase Hdl-C In Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (Types Iia, Iib) And To Treat Hypertriglyceridemia (Types Iv, V)
    U-848 Acute Treatment Of Migraine With Or Without Aura
    U-849 Reduction Of Elevated Intraocular Pressure (Iop) In Patients With Glaucoma Or Ocular Hypertension Who Require Adjunctive Or Replacement Therapy Due To Inadequately Controlled Iop. Dose Is One Drop Of Combigan In The Affected Eye Twice Daily
    U-85 Nasal Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms
    U-850 Prevention Or Treatment Of Nausea Or Emesis Induced By A Cancer Chemotherapeutic Agent
    U-851 Treatment Of Type 2 Diabetes Mellitus
    U-852 Relief Of Symptoms Associated With Seasonal And Perennial Allergic Rhinitis
    U-853 Treatment Or Prevention Of Emesis
    U-854 Prevention Of Cmv Disease In Kidney, Heart, And Kidney-Pancreas Transplant Patients At High Risk (Donor Cmv Seropositive/Recipient Cmv Seronegative)
    U-855 Method To Induce Natriuresis, Diuresis And/Or Vasodilation
    U-856 Support Embryo Implantation And Early Pregnancy By Supplementation Of Corpus Luteal Function As Part Of An Assisted Reporductive Technology (Art) Treatment Program For Infertile Women
    U-857 Inhibition Of Transplant Rejection
    U-858 Pediatric Use Aged 1-11 Years, Gerd And Erosive Esophagitis
    U-859 Erosive Esophagitis, Hypersecretory Conditions Including Zollinger-Ellison Syndrome, Maintenance Of Healing Of Erosive Esophagitis And Reduction Of Symptoms In Patients With Gerd
    U-86 Method Of Treating Certain Forms Of Epilepsy
    U-860 For The Approved Uses And Conditions Of Use, Including Depression
    U-861 Relief Of The Inflammatory And Pruritic Manifestations Of Corticosteroid Responsive Dermatoses In Patients 12 Years Of Age Or Older
    U-862 Adjunct To Diet To Reduce Elevated Total-C, Ldl-C, Non-Hdl-C, Apo B, Tg, And Lp(A) Levels And To Increase Hdl-C In Patients With Primary Hypercholesterolemia, Mixed Dyslipidemia, And Hypertriglyceridemia
    U-863 Taking Aspirin Or Non-Steroidal Anti-Inflammatory Medications Approximately 30 Minutes Before Dosing Can Minimize Flushing, A Common Side Effect Of Niacin Therapy
    U-864 Pediatric Use Ages 1-2 Years, Gerd And Erosive Esophagitis
    U-865 Treatment Of A Woman With Osteoporosis And A High Risk For Bone Fracture By Reducing The Risk Of Vertebral And Nonvertebral Bone Fracture
    U-866 The Label References The Effects Of The Active Ingredient Of Revlimid Upon Cytokines
    U-867 Treatment Of Migraine
    U-868 Method Of Using Antagonist Of Arginine Vasopressin (Ava) V1a And V2 Receptors For Intravenous Treatment Of Patients With Hypervolemic Hyponatremia
    U-869 Method For Stimulating Coronoary Vasodilation For Purposes Of Imaging The Heart
    U-87 Method For Noninvasive Administration Of Sedatives, Analgesics, And Anesthetics
    U-870 Method Of Producing Coronary Vasodilation Without Peripheral Vasodilation
    U-871 Method Of Reducing Risk Of Myocardial Infarction, Stroke And Death
    U-872 Twice Daily Maintenance Treatment Of Airflow Obstruction In Patients With Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And Emphysema. To Reduce Exacerbations Of Copd In Patients With A History Of Exacerbations
    U-873 Method Of Treating Constipation In A Patient With Irritable Bowel Syndrome By Opening Chloride Channels (Cic)
    U-874 Method Of Treating Constipation In A Patient With Irritable Bowel Syndrome
    U-875 First-Line Treatment Of Locally Advanced Unresectable Or Metastatic Pancreatic Cancer, In Combination With Gemcitabine
    U-876 Treatment Of Migraine With Or Without Aura
    U-877 For Use As Adjunctive Therapy In The Treatment Of Peptic Ulcer
    U-878 A Method For Binding A Peripheral Opioid Receptor
    U-879 A Method Of Treating Or Preventing Ileus
    U-88 Treatment Of Moderate Plaque Psoriasis
    U-880 Endometrin Is A Progesterone Indicated To Support Embryo Implantation And Early Pregnancy By Supplementation Of Corpus Luteal Function As Part Of An Assisted Reproductive Technology (Art) Treatment Program For Infertile Women
    U-881 Treatment Of Non-Small Cell Lung Cancer
    U-882 Management Of Fibromyalgia (Fm)
    U-883 Treatment Of Gastrointestinal Stromal Tumor With Sunitinib
    U-884 Treatment Of Patients With Multiple Myeloma
    U-885 Treatment Of Patients With Mantle Cell Lymphoma Who Have Received At Least 1 Prior Therapy
    U-886 Administering Desloratadine To Treat The Symptoms Of Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis, Or Chronic Idiopathic Urticaria
    U-887 Treatment And Prevention Of Osteoporosis
    U-888 Female Hormone Replacement Therapy For Postmenopausal Women
    U-889 Menopausal And Postmenopausal Disorders (Including Vasomotor Symptoms Assocciated With Menopause)
    U-89 Treatment Or Prophylaxis Of Emesis
    U-890 Reduction Of Serum Phosphate In Patients With End Stage Renal Disease
    U-891 Use As An Intraocular Irrigating Solution During Surgical Procedures Involving Perfusion Of The Eye
    U-892 Treatment Of Cutaneous Manifestations In Patients Wtih Cutaneous T-Cell Lymphoma (Ctcl)
    U-893 Cleviprex Is A Dihydropyridine Calcium Channel Blocker Indicated For The Reduction Of Blood Pressure When Oral Therapy Is Not Feasible Or Not Desirable
    U-894 Treatment Of Cold Sores In Pediatric Patients Twelve Years Of Age And Older
    U-895 Treatment Of Hiv Infection In Combination With Other Antiretroviral Agents
    U-896 Treatment Of Nasal Symptoms Of Seasonal And Perennial Allergic Rhinitis In Adults And Children Two Years Of Age And Older
    U-897 Method Of Treating Tonsillitis And/Or Pharyngitis Secondary To Streptococcus Pyogenes In A Once-A-Day Amoxicillin Product
    U-898 Use Of Glutamine Together With Growth Hormone For The Treatment Of Patients With Short Bowel Syndrome
    U-899 Use Of Thalidomide In Combination With Dexamethasone For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma
    U-9 Control Of Emesis Associated With Any Cancer Chemotherapy Agent
    U-90 Treatment Of Pyschotic Disorders
    U-900 Integrase Inhibition For The Treatment Of Hiv Infection
    U-901 Prevention Of Postoperative Nausea And Vomiting
    U-902 Use In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia (Bph)
    U-903 Treatment Of Human Immunodeficiency Virus (Hiv) In Adult Patients
    U-904 Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause
    U-905 Treatment Of Moderate To Severe Vaginal Dryness And Pain With Intercourse, Symptoms Of Vulvar And Vaginal Atrophy, Associated With Menopause
    U-906 Prophylaxis Of Organ Rejection In Kidney, Liver And Heart Allogenic Transplants; Treatment Of Patients With Severe Active, Rheumatoid Arthritis; Treatment Of Adult, Nonimmunocompromised Patients With Severe, Recalcitrant, Plaque Psoriasis
    U-907 For The Maintenance Of Remission Of Ulcerative Colitis In Subjects 18 Years Of Age And Older
    U-908 Prophylaxis Of Organ Rejection In Patients Receiving Allogeneic Renal Transplants
    U-909 Treatment Of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
    U-91 Alternative Therapy To Trimethoprim-Sulfamethoxazole For Treatment Of Moderate-To-Severe Pneumocystis Carinii Pneumonia In Immunocompromised And Aids Patients
    U-910 Treatment Of Metastatic Carcinoma Of The Ovary After Failure Of Initial Or Subsequent Chemotherapy
    U-911 Method Of Treating, As Adjunctive Therapy, Partial-Onset Seizures In A Patient With Epilepsy Aged 17 Years And Older When Oral Treatment Is Temporarily Not Feasible
    U-912 Sedation Of Non-Intubated Patients Prior To And/Or During Surgical And Other Procedures
    U-913 Treatment Of Overactive Bladder With Symptoms Of Urge Urinary Incontinence, Urgency, And Frequency
    U-914 Method Of Treating, As Adjunctive Therapy, Partial-Onset Seizures In A Patient With Epilepsy Aged 17 Years And Older
    U-915 Treatment Of Musculoskeletal Conditions
    U-916 Topical Treatment Of Acne Vulgaris In Patients 12 Years Or Older
    U-917 Treatment Of Inflammatory Lesions Of Non-Nodular Moderate To Severe Acne Vulgaris
    U-918 To Treat Or Prevent Infections Caused By Susceptible Bacteria Using Delayed-Release Tablets Consisting Of Doxycycline Hyclate Coated Pellets In A Tablet
    U-919 For The Treatment Of Dermatitis
    U-92 Treatment Of Diabetic Nephropathy In Patients With Type I Insulin Dependent Diabetes Mellitus And Retinopaty
    U-920 Steroid-Responsive Inflammatory Ocular Conditions For Which A Corticosteroid Is Indicated And Where Superficial Bacterial Ocular Infection Or A Risk Of Bacterial Ocular Infection Exists
    U-921 Treatment Of Acne Vulgaris
    U-922 For The Treatment Of Fungal Infections
    U-923 Method Of Treating Ophthalmic Inflammation And Infection
    U-924 Treatment Of Mild To Moderate Infection Caused Aby Susceptible Strains
    U-925 Treatment Of Only Inflammatory Lesions (Papules And Pustiles) Of Rosacea
    U-926 Mgt Specific Bacterial Infections. Treatment Pts W/ Community Acquired Pneumonia Or Bacterial Sinusitis Due To Confirmed, Or Suspected B-Lactamase Producing Pathogens & S. Pneumoniae With Reduced Susceptibility To Penicillin (Mic=2mc/Ml)
    U-927 Method For Increasing Tear Production
    U-928 Treatment Of Bacterial Infectious Disease
    U-929 Treatment Of Obsessive Compulsive Disorder Treatable With An Ssri
    U-93 Use As An Antihistamine/Decongestant
    U-930 Treatment Of Idiopathic Thrombocytopenic Purpura (Itp)
    U-931 Relief Of Moderate To Severe Acute Pain
    U-932 Pylera Capsules, In Combination With Omeprazole Are Indicated For The Treatment Of Patients With Helicobacter Pylori Infection And Duodenal Ulcer Disease To Eradicate H. Pylori
    U-933 For The Treatment Of Patients With Helicobacter Pylori Infection And Duodenal Ulcer Disease To Eradicate H. Pylori. The Eradication Of Helicobacter Pylori Has Been Shown To Reduce The Risk Of Duodenal Ulcer Recurrence
    U-934 In Combination With Granulocyte-Colony Stimulating Factor (G-Csf) To Mobilize Hematopoietic Stem Cell To The Peripheral Blood For Collection And Subsequent Autologous Transplantation With Non-Hodgkins Lymphoma And Multiple Myeloma
    U-935 Treatment Of Human Immunodeficiency Virus (Hiv) Infection In Adult Patients, And Treatment Of Human Immunodeficiency Virus (Hiv) In Pediatric Patients 6 Years Of Age And Older
    U-936 Use In Combination With Granulocyte-Colony Stimulating Factor (G-Csf) To Mobilize Hematopoietic Stem Cells To Peripheral Blood For Collection & Subsequent Autologous Transplantation In Patients With Non-Hodgkin's Lymphoma & Multiple Myeloma
    U-937 Treatment Of Prostate Cancer
    U-938 Treatment Of Hair Loss And Hypotrichosis Of The Eyelashes By Increasing Their Growth Including Length, Thickness And Darkness
    U-939 Treatment Of Hypotrichosis Of The Eyelashes By Increasing And Stimulating Their Growth Including Length, Thickness And Darkness
    U-94 Treatment-Adults W/ Advanced Hiv,Intolerant Of Approved Therapies,Intolerant Of Approved Therapies W/Proven Benefit Or Have Experienced Clinical/Immunological Deterioration While Receiving..Or For Whom Such Therapies-Contraindicated
    U-940 Method To Treat Aids-Related Kaposi's Sarcoma
    U-941 Method To Treat Ovarian Cancer
    U-942 Method To Treat Multiple Myeloma
    U-943 Gnrh Antagonist Indicated For Treatment Of Patients With Advanced Prostate Cancer
    U-944 Treatment Of Patients With B-Cell Chronic Lymphocytic Leukemia (Cll)
    U-945 Sedative-Hypnotic Agent Indicated For Monitored Anesthesia Care (Mac) Sedation
    U-946 Treatment Of Breast Cancer
    U-947 When Patients Are Unable To Take The Oral Formulations, Prevacid Iv, For Injection Is Indicated As An Alternative For The Short-Term Treatment (Up To 7 Days) Of All Grades Of Erosive Esophagitis
    U-948 Treatment Of Diabetes Mellitus
    U-949 Healing Of All Grades Of Erosive Esophagitis (Ee) For Up To 8 Weeks
    U-95 Short Term Management Of Moderate Pruritis In Adults With Atopic Dermatitis And Lichen Simplex Chronicus
    U-950 Maintain Healing Of Erosive Esophagitis (Ee) For Up To 6 Months
    U-951 Treatment Of Heartburn Associated With Non-Erosive Gastroesophageal Reflux Disease (Gerd) For 4 Weeks
    U-952 Use As An Analgesic
    U-953 Method Of Treating Ophthalmic Inflammation And Infection
    U-954 Chronic Management Of Hyperuricemia In Patients With Gout. Not Recommended For The Treatment Of Asymptomatic Hyperuricemia
    U-955 Prophylactic Treatment Of Migraine
    U-956 Treatment Of Patients With H. Pylori Infection And Duodenal Ulcer Disease
    U-957 A Method Of Treating Cancer In A Patient Comprising Administering Ixabepilone Or Pharmaceutical Compositions Comprising Ixabepilone
    U-958 Method Of Treating Patient Comprising Mixing First And Second Vials Of Product Comprising Lyophilized Ixabepilone To Provide An Epothilone Analog Solution, Diluting Solution With A Suitable Diluent To Prepare Intravenous Formulation For Pt
    U-959 Method Of Treating Cancer, Iv Admin, Lyophylized Ixabepilone Diluted, Every Week Or 3 Weeks; Lyophilized Ixabepilone With Solvent(Dehydrated Ethanol) Diluted To Concentration Of 0.1mg/Ml To 0.9mg/Ml
    U-96 Method Of Treating Varicella Zoster (Shingles) Infections
    U-960 Method Of Treating Cancer In A Patient Comprising Intravenously Administering To The Patient Ixabepilone Diluted In A Parenteral Diluent
    U-961 Method Of Treating Breast Cancer By Administering Ixabepilone; A Method Of Treating A Cancer Responsible To Microtubule Stabilization By Administering Ixabepilone
    U-962 Symbyax Is Indicated For The Acute Treatment Of Treatment Resistant Depression In Adults
    U-963 Prozac And Olanzapine In Combination For The Acute Treatment Of Treatment Resistant Depression In Adults
    U-964 Zyprexa Zydis And Fluoxetine In Combination For The Acute Treatment Of Treatment Resistant Depression In Adults
    U-965 Use Of Ixabepilone In Combination With Capecitabine In Treatment Of Metastasis Breast Cancer
    U-966 Treatment Of Asthma (Maintenance And Prophylactic Therapy)
    U-967 A Method Of Reversing Soft-Tissue Anesthesia I.E. Anesthesia Of The Lip And Tongue, And The Associated Functional Deficits Resulting From An Intraoral Submucosal Injection Of A Local Anesthetic
    U-968 A Method For Improving Glycemic Control In Adults With Type 2 Diabetes Mellitus
    U-969 Treatment Of Migraine
    U-97 A Method Of Treating A Patient In Need Of Memory Enhancement
    U-970 Topical Treatment Of Lice Infestations
    U-971 Indicated For The Acute Treatment Of Adults With Schizophrenia
    U-972 Monotherapy Or As Adjunctive Therapy To Lithium Or Valproate For The Maintenance Treatment Of Bipolar I Disorder
    U-973 Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus Who Are Already Treated With Pioglitazone And Metformin Or Who Have Inadequate Glycemic Control On Pioglitazone Or Metformin Alone
    U-974 Adjunct To Diet And Exercise To Improve Glycemic Control In Patients With Type 2 Diabetes Who Are Already Treated With A Pioglitazone And Metformin
    U-975 Treatment Of Pulmonary Hypertension
    U-976 Improvement Of Glycemic Control In Individuals With Type 2 Diabetes
    U-977 Treatment Of Acute, Uncomplicated Malaria Infection Due To Plasmodium Falciparum In Patients Of 5kg Bodyweight And Above
    U-978 Method Of Treating Hyponatremia
    U-979 Relief Of Muscle Spasm
    U-98 A Method Of Inducing Regression Of Leukemia Cell Growth In A Mammal
    U-980 Nonsteroidal Anti-Inflammatory Drug Indicated For Relief Of Mild To Moderate Acute Pain
    U-981 Management Of Mild To Moderate Pain, Management Of Moderate To Severe Pain As An Adjunct To Opioid Analgesics, Reduction In Fever Through Anti-Inflammatory, Analgesic, And Antipyretic Activity
    U-982 A Method Of Treating Osteoporosis
    U-983 Method Of Treating Osteoporosis In A Post-Menopausal Woman At Risk For Fracture
    U-984 Method For The Treatment Of A Woman With Osteoporosis And At Risk For Bone Fracture
    U-985 Treatment Of Macular Edema Following Branch Retinal Vein Occlusion (Brvo) Or Central Retinal Vein Occlusion (Crvo)
    U-986 Treatment Of Patients Infected With Pediculus Humanus Capitis (Head Lice And Their Ova) Of The Scalp Hair
    U-987 Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease On Dialysis
    U-988 Treatment Of Rhinitis Comprising The Nasal Application Of A Pharmaceutical Formulation As Claimed In Us Patent 7541350
    U-989 For Reducing Blood Phenylalanine Levels In A Human Suffering From Hyperphenylalaninemia
    U-99 Method Of Providing Potassium To A Subject In Need Of Potassium
    U-990 Treatment Of Protozoal Infection
    U-991 Treatment Or Prophylaxis Of Thrombosis Or Embolisms
    U-992 Reduction Of The Risk Of Cardiovascular Hospitalization
    U-993 Method Of Treating Infertility
    U-994 Method Of Treatment Of Osteoporosis Wherein The Osteoporosis Is Steroid-Induced
    U-995 Method For Treating Type Ii Diabetes By Administering Saxagliptin
    U-996 An Adjunctive Therapy To Diet To Reduct Elevated Total Chloresterol (Tc), Low-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, And To Increase Hdl-C In Adult Patients With Primary Hyperlipidemia Or Mix Dyslipidemia
    U-997 Treatment Of Major Depressive Disorder By Dosing At Intervals Of 24 Hours
    U-998 Adjuncitve Therapy To Diet To Reduce Elevated Total Cholesterol, Low-Density Lipoprotein Cholesterol, Apolipoprtein B, Triglycerides And To Increase Hdl-C In Adult Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
    U-999 Treatment Of Chronic Hepatitis B In Adult Patients
    其他库:化学品法规 中国专利 国际专利 国家标准 国际标准 化学品安全数据库(msds) 外贸常识 合同范本 报关指南 商检指南 国际区号 国家代码